Chimeric neurotrophy AAV capsid

Chimeric AAV capsids with targeted amino acid substitutions enhance neuronal cell infectivity, addressing the limitations of AAV9 vectors by improving gene delivery efficacy in the central nervous system.

CN119095866APending Publication Date: 2024-12-06THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
View PDF 41 Cites 0 Cited by

Patent Information

Application Number
CN202380035145.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-22
Filing Date
2023-02-22
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing AAV9 vectors are limited by pre-existing neutralizing antibodies in patients, preventing effective gene therapy in the central nervous system due to low infectivity in neuronal cells.

Method used

Development of chimeric AAV capsids with specific amino acid substitutions in VP1, VP2, and VP3 proteins, enhancing neurotropic properties and infectivity to neuronal cells.

Benefits of technology

The chimeric AAV capsids demonstrate improved infectivity and gene delivery efficiency in neural cells, including spinal cord and dorsal root ganglia, with potential therapeutic applications in treating CNS disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095866A_ABST
    Figure CN119095866A_ABST
Patent Text Reader

Abstract

The present invention relates to modified chimeric AAV capsids, viral vectors comprising the chimeric AAV capsids, and methods of using the vectors, such as targeting the nervous system. The invention further relates to modified chimeric AAV capsids having improved infectivity to nerve cells, viral vectors comprising the chimeric AAV capsids, and methods of using the vectors for improved infectious targeting of nerve cells.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority declaration

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 312,569, filed on February 22, 2022, under 35 U.S.C. §119(e), which is incorporated herein by reference in its entirety.

[0003] Statement Concerning Electronic Submission of Sequence Listings

[0004] The disclosure of the sequence listing in XML format, entitled 5470-923WO_ST26.xml, 43,550 bytes in size, generated on February 20, 2023 and submitted herewith, is hereby incorporated by reference in its entirety. Technical Field

[0005] The present invention relates to chimeric AAV capsids, viral vectors comprising the chimeric AAV capsids, and methods of using the vectors, such as for targeting the nervous system. The present invention further relates to chimeric AAV capsids with improved infectivity to neural cells (e.g., cells of the central and / or peripheral nervous system), viral vectors comprising the chimeric AAV capsids, and methods of using the vectors to target neural cells with improved infectivity. Background Art

[0006] Adeno-associated virus (AAV) is a candidate for the treatment of central nervous system (CNS) diseases, especially AAV serotype 9 has CNS affinity and effectively delivers genes in the CNS. However, in the human population, 33.5% of patients have pre-existing neutralizing antibodies against AAV9 (anti-AAV9) (Boutin et al. 2010 Hum Gene Ther. 21 (6): 704-712), which limits the application of AAV9 therapy in the clinic, because pre-existing NAbs can prevent AAV vector transduction and often lead to the failure of the proposed gene therapy program (Erles et al. 1999 J med Virol 59 (3): 406-411; Li et al. 2012 Gene Ther. 1993): 288-94; Louis Jeune et al. 2013 Hum Gene Ther Methods 24 (2): 59-67; Murphy et al. 2008 Mol Ther 16 (1): 138-145). Therefore, there is a need to find new AAV vectors that can effectively infect neuronal cells.

[0007] The present invention overcomes shortcomings in the art by providing modified chimeric AAV capsids with improved infectivity to neuronal cells. Summary of the invention

[0008] One aspect of the invention comprises a chimeric adeno-associated virus (AAV) capsid of a first serotype, comprising a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein of the first serotype, wherein: a) the VP1 capsid protein and / or the VP2 capsid protein comprises one or more substitutions at amino acid positions 24, 41, 125, 129, 135, 147, 159, 162, 164, 168, 194, 196, 197, 198, 200, 201, 203, 205, 224, 233 and / or 235, and b) the VP3 capsid protein comprises one or more amino acid substitutions in the VP3 variable region (VR); wherein the numbering corresponds to SEQ ID NO: 16, and wherein the chimeric AAV capsid has enhanced neurotropic properties compared to the neurotropic properties of the corresponding wild-type AAV capsid of the first serotype.

[0009] In some embodiments, one or more amino acid substitutions in VP3 VR may be in VP3 VR-I, VR-II, VR-III, VR-IV, VR-V, VR-VI, VR-VII, VR-VIII, the HI loop, and / or VR-IX.

[0010] In some embodiments, the chimeric AAV vector can be covalently linked, bound, or encapsidated with a compound selected from the group consisting of a DNA molecule (e.g., Cas9-plasmid), an RNA molecule (e.g., CRISPR RNA), a polypeptide, a carbohydrate, a lipid, a small organic molecule, and any combination thereof (e.g., CRISPR RNP).

[0011] Another aspect of the present invention provides an AAV particle comprising: a chimeric AAV capsid of the present invention; and an AAV vector genome; wherein the AAV capsid encapsidates the AAV vector genome.

[0012] In another aspect, the invention provides nucleic acid molecules encoding the chimeric AAV capsids of the invention.

[0013] In another aspect, the present invention provides a vector comprising a nucleic acid molecule of the present invention.

[0014] In another aspect, the invention provides a cell (eg, an in vitro cell) comprising a chimeric particle, nucleic acid molecule and / or vector of the invention.

[0015] Also provided are pharmaceutical formulations comprising the AAV particles, nucleic acid molecules and / or vectors of the invention in a pharmaceutically acceptable carrier.

[0016] Another aspect of the invention comprises a method for producing recombinant AAV particles comprising an AAV capsid, the method comprising: providing / introducing into cells in vitro the nucleic acid molecule of the invention, the AAV rep coding sequence, the AAV vector genome and helper functions for generating a productive AAV infection under conditions whereby assembly of the recombinant AAV particles comprising the AAV capsid and encapsidating an AAV vector genome comprising a heterologous nucleic acid molecule can occur.

[0017] Also provided are AAV particles produced by the methods of the invention.

[0018] Another aspect of the invention provides a method for delivering a nucleic acid molecule to a neural cell (e.g., including cells of the peripheral and central nervous systems, e.g., brain cells such as neurons, oligodendrocytes, glial cells, microglia, astrocytes, e.g., spinal cord such as cervical, thoracic, lumbar, sacral neurons and / or dorsal root ganglia (DRG)), the method comprising contacting the neural cell with an AAV particle, nucleic acid molecule, vector, cell and / or pharmaceutical formulation of the invention.

[0019] Another aspect of the present invention provides a method for delivering a nucleic acid molecule to neural cells of a mammalian subject, the method comprising: administering an effective amount of the AAV particles, nucleic acid molecules, vectors, cells and / or pharmaceutical formulations of the present invention, thereby delivering the nucleic acid molecule to the neural cells of the mammalian subject.

[0020] Another aspect of the invention provides a method of treating a disorder (e.g., a CNS disorder, e.g., a PNS disorder) in a mammalian subject in need thereof, wherein the disorder can be treated by expressing a nucleic acid molecule encoding a therapeutic product in the nervous system of the subject, the method comprising administering to the mammalian subject a therapeutically effective amount of the AAV particles, nucleic acids, vectors, cells and / or pharmaceutical formulations of the invention under conditions such that the nucleic acid molecule encoding the therapeutic product is expressed in the nervous system, thereby treating the disorder. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Image showing sequence alignment between example chimeric capsids AAVH43 (SEQ ID NO: 1), AAVH48 (SEQ ID NO: 6), and AAVH67 (SEQ ID NO: 11) compared to AAV9 (SEQ ID NO: 21) and AAV6 (SEQ ID NO: 16).

[0022] Figure 2An image showing an alignment of the variable region (VR) portions contained within AAVH43 (SEQ ID NO: 1), AAVH48 (SEQ ID NO: 6), and AAVH67 (SEQ ID NO: 11) and AAV9 (SEQ ID NO: 21) and AAV6 (SEQ ID NO: 16) located at the numbered positions as indicated. Compared to AAV9, AAVH43, AAVH48, and AAVH67 present differences primarily in VR-I and VR-VIII.

[0023] Figure 3 Histological images showing AAV-mediated GFP expression in the liver and heart. AAV9 and AAV6 showed different tissue tropism in the liver via tail vein injection. AAV dose: 3 × 10 11 / mouse, n=4.

[0024] Figure 4 Histological images showing LacZ expression in the lumbar spinal cord. LacZ gene delivery by AAVH43, AAVH48, and AAVH67 vectors was efficiently and similarly expressed in the lumbar spinal cord by intrathecal injection.

[0025] Figure 5 Histological images showing LacZ expression in the cervical spinal cord. LacZ gene delivered by AAVH43, AAVH48, and AAVH67 vectors was expressed efficiently and similarly to AAV9 in the cervical spinal cord by intrathecal injection. (n=4)

[0026] Figure 6 Shows histological images indicating the distribution of LacZ gene expression in the lumbar spinal cord. Infected cells are mainly distributed in the posterior cord and gray matter.

[0027] Figure 7 Shows histological images indicating the distribution of LacZ gene expression in the cervical spinal cord. Infected cells are mainly distributed in the posterior column and gray matter.

[0028] Figure 8 Histological images indicating the distribution of LacZ gene expression in dorsal root ganglia at the lumbar segment are shown. All four vectors infected dorsal root ganglion neurons very efficiently.

[0029] Fig. 9 Histological images indicating the distribution of LacZ gene expression in dorsal root ganglia at the cervical segment are shown. All four vectors infected dorsal root ganglion neurons very efficiently.

[0030] Fig.10Histological images showing immunostaining for LacZ and NeuN in the anterior horn. Immunostaining showed that AAVH43, AAVH48, and AAVH67 vectors with CMV promoter predominantly infect neurons, similar to AAV9. Panel staining from left to right: anti-LacZ; anti-NeuN (staining for neuronal cells); DAPI; merge.

[0031] Fig.11 Histological images showing immunostaining for LacZ and glial fibrillary acid protein (GFAP) in the anterior horn. Immunostaining shows that AAVH43, AAVH48, and AAVH67 vectors with CMV promoter do not infect glial cells, similar to AAV9. Grouped staining from left to right: anti-LacZ; anti-GFAP (glial cells); DAPI; merge.

[0032] Fig.12 Histological images showing immunostaining for dorsal root ganglion. LacZ expression in the cytoplasm of dorsal root ganglion neurons. Grouped staining from left to right: anti-LacZ; anti-NeuN (staining for neuronal cells); DAPI; merge.

[0033] Fig.13 Histological images indicating the distribution of LacZ expression in the cerebellar cortex are shown. AAVH43 and AAVH48 share some common features and infect the cerebellar cortex much more efficiently than AAV9. Those neurons show a unique morphology as Purkinje cells.

[0034] Fig.14 Shown are histological images indicating the distribution of LacZ expression in the brainstem and cortex.

[0035] Fig.15 Shown are histological images indicating the distribution of LacZ expression in the brain by AAVH43, H48, and H67 vectors compared to AAV9 via intracerebroventricular injection into newborn mouse pups. AAV dose: 5×10 12 vg / mL, 5 μL injected into each lateral ventricle, n=4.

[0036] Fig.16 Data graph showing ALS survival of mice treated with AAVH67-CMV-thymosin. AAVH67-mediated thymosin expression in the CNS extended ALS survival from 133 days to 145 days via intrathecal injection. ALS control group, n=20; AAVH67 treatment, n=16; half male and half female; P<0.001, log-rank test.

[0037] Fig.17Data graph showing time to ALS progression in mice treated with AAVH67-CMV-thymosin. Fig.17 Center (A) shows that AAVH67-mediated thymosin expression in the CNS increased ALS survival from 128.9±2.6 days to 141.7±1.9 days. Fig.17 Middle B shows that AAVH67-mediated thymosin expression in the CNS via intrathecal injection delayed ALS progression from 26.5±1.9 days to 34.0±2.1 days. ALS control group, n=20; AAVH67 treatment, n=16; half male and half female; *P<0.05, ***P<0.001, relative to ALS untreated group as control. t-test.

[0038] Fig.18 Data graphs indicating disease onset are shown. AAVH67-mediated thymosin expression in the CNS via intrathecal injection extended ALS disease onset from 101.5 days to 108.5 days. ALS control group, n=20; AAVH67 treatment, n=16; half male and half female; P<0.05, log-rank test. DETAILED DESCRIPTION

[0039] The present invention will now be described hereinafter with reference to the accompanying drawings and examples showing embodiments of the present invention. The description is not intended to be an exhaustive list of all the different ways in which the present invention can be implemented or all the features that can be added to the present invention. For example, the features described for one embodiment may be incorporated into other embodiments, and the features described for a particular embodiment may be deleted from the embodiment. Therefore, it is contemplated that in some embodiments of the present invention, any feature or feature combination described herein may be excluded or omitted. In addition, it will be apparent to those skilled in the art that many variations and additions of the various embodiments proposed herein will be apparent from the present disclosure, and that they do not depart from the present invention. Therefore, the following description is intended to illustrate some specific embodiments of the present invention, rather than to exhaustively specify all permutations, combinations, and variations thereof.

[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. The terms used in the description of the invention herein are for the purpose of describing specific embodiments only and are not intended to limit the invention.

[0041] All publications, patent applications, patents, and other references cited herein are incorporated by reference in their entirety for the teachings relevant to the sentence and / or paragraph in which the reference is presented.

[0042] Unless the context indicates otherwise, it is expressly intended that the various features of the invention described herein may be used in any combination. In addition, the present invention also contemplates that in some embodiments of the present invention, any feature or combination of features described herein may be excluded or omitted. For example, if the specification states that the composition comprises components A, B, and C, it is expressly intended that any one or combination of A, B, or C may be omitted and abandoned, either individually or in any combination.

[0043] As used in the description of the invention and the appended claims, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0044] Also as used herein, "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of a combination when interpreted in the alternative ("or").

[0045] As used herein, the term "about" when referring to a measurable value, such as an amount or concentration, is intended to cover the specified value and variations of ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified value. For example, "about X" where X is a measurable value is intended to include X and variations of ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of X. The ranges of measurable values ​​provided herein may include any other ranges and / or individual values ​​therein.

[0046] As used herein, phrases such as "between X and Y" and "between about X and Y" should be interpreted to include X and Y. As used herein, phrases such as "between about X and Y" mean "between about X and about Y," and phrases such as "from about X to Y" mean "from about X to about Y."

[0047] As used herein, the terms “comprise,” “comprises,” and “comprising” specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof.

[0048] As used herein, the transitional phrase "consisting essentially of" means that the scope of the claim should be interpreted to include the specified materials or steps described in the claim as well as materials or steps that do not materially affect the basic and novel characteristics of the claimed invention. Therefore, when used in the claims of the present invention, the term "consisting essentially of" is not intended to be interpreted as being equivalent to "comprising".

[0049] Unless otherwise indicated, standard methods known to those skilled in the art can be used for cloning genes, amplifying and detecting nucleic acids, etc. Such techniques are known to those skilled in the art. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 4th Edition (Cold Spring Harbor, NY, 2014); Ausubel et al., Current Protocols in Molecular Biology (Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York).

[0050] Unless otherwise expressly indicated, nucleotide sequences are presented herein only in a single strand from left to right in the 5' to 3' direction. Nucleotides and amino acids are referred to herein in the manner recommended by the IUPAC-IUB Biochemical Nomenclature Commission, or (for amino acids) by the single-letter code or the three-letter code, both in accordance with 37 C.FR § 1.822 and established usage.

[0051] To further illustrate, if, for example, the specification indicates that a particular amino acid can be selected from A, G, I, L, and / or V, the language also indicates that the amino acid can be selected from any subset of these amino acids, such as A, G, I, or L; A, G, I, or V; A or G; only L; etc., as if each such subset is expressly set forth herein. In addition, such language also indicates that one or more of the specified amino acids can be disclaimed (e.g., by a negation condition). For example, in a particular embodiment, the amino acid is not A, G, or I; is not A; is not G or V; etc., as if each such possible disclaimer is expressly set forth herein.

[0052] All amino acid positions in the AAV capsid proteins in the AAV vectors and recombinant AAV nucleic acid molecules of the present invention are designated with respect to the VP1, VP2 and / or VP3 capsid subunit numbering identified as SEQ ID NO: 17 (AAV6 VP1+VP2) and SEQ ID NO: 18 (AAV6 VP3), and / or the wild-type AAV6 VP1, VP2 and VP3 capsid proteins Accession number: AAB95450.1 (SEQ ID NO: 16).

[0053] Those skilled in the art will appreciate that modifications as described herein, if inserted into the AAV cap gene, can result in modifications in VP1, VP2 and / or VP3 capsid subunits. Alternatively, the capsid subunits can be expressed independently to achieve modifications in only one or two capsid subunits (VP1, VP2, VP3, VP1+VP2, VP1+VP3 or VP2+VP3).

[0054] As used herein, the terms "reduce," "reduces," "reduction," "diminish," "inhibit," and the like mean a reduction of at least about 5%, 10%, 15%, 20%, 25%, 35%, 50%, 75%, 80%, 85%, 90%, 95%, 97% or more.

[0055] As used herein, the terms "enhance," "enhances," "enhancement" and similar terms indicate an increase of at least about 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400%, 500% or more.

[0056] As used herein, the term "parvovirus" encompasses Parvoviridae, including autonomously replicating parvovirus and dependent viruses. Autonomous parvoviruses include members of the genus Parvovirus, Erythrovirus, Densovirus, Iteravirus, and Contravirus. Exemplary autonomous parvoviruses include, but are not limited to, mouse parvovirus, bovine parvovirus, canine parvovirus, chicken parvovirus, feline panleukopenia virus, feline parvovirus, goose parvovirus, H1 parvovirus, duck parvovirus, B19 virus, and any other autonomous parvovirus known or found later. Other autonomous parvoviruses are known to those skilled in the art. See, for example, BERNARD N.FIELDS et al., VIROLOGY, Vol. 2, Chapter 69 (4th Edition, Lippincott-Raven Publishers).

[0057] As used herein, the term "adeno-associated virus" (AAV) includes, but is not limited to, AAV type 1, AAV type 2, AAV type 3 (including type 3A and type 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, AAV type 11, AAV type 12, AAV type 13, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, any serotype listed in Table 1, and any other AAV now known or later discovered. See, e.g., BERNARD N. FIELDS et al., Virology, Vol. 2, Chapter 69 (4th ed., Lippincott-Raven Publishers). Many additional AAV serotypes and clades have been identified (see, e.g., Gao et al., (2004) J. Virology 78:6381-6388; Mori et al., (2004) Virology 33:375-383; and Table 1).

[0058] The genome sequences of various serotypes of AAV and autonomous parvoviruses, as well as the sequences of native terminal repeats (TRs), Rep proteins, and capsid subunits are known in the art. Such sequences can be found in the literature or in public databases such as ). These sequences include known amino acid sequences of serotype capsid proteins, including but not limited to AAD27757.1 (AAV1), YP_068409.1 (AAV5), AAC03780.1 (AAV2), AAC58045.1 (AAV4), NP_043941.1 (AAV3), AAB95450.1 (AAV6), YP_077178.1 (AAV7), YP_077180.1 (AAV8), AAS99264.1 (AAV9). See also, for example Accession Nos. NC_002077, NC_001401, NC_001729, NC_001863, NC_001829, NC_001862, NC_000883, NC_001701, NC_001510, NC_006152, NC_006261, AF063497, U89790, AF043303, AF028705, AF028 704, J02275, J01901, J02275, X01457, AF288061, AH009962, AY028226, AY028223, NC_001358, NC_001540, AF513851, AF513852, AY530579; the disclosures of which are incorporated herein by reference for teaching parvovirus and AAV nucleic acid and amino acid sequences. See also, e.g., Srivistava et al. (1983) J. Virology 45:555; Chiorini et al. (1998) J. Virology 71:6823; Chiorini et al. (1999) J. Virology 73:1309; Bantel-Schaal et al. (1999) J. Virology 73:939; Xiao et al. (1999) J. Virology 73:3994; Muramatsu et al. (1996) Virology 221:208; Shade et al. (1986) J. Virol. 58:921; Gao et al. (2002) Proc. Nat. Acad. Sci. USA 99:11854; Mori et al. (2004) Virology 33:375-383; International Patent Publication Nos. WO 00 / 28061, WO 99 / 61601, WO 98 / 11244; and U.S. Patent No. 6,156,303; the disclosures of which are incorporated herein by reference for teachings of parvovirus and AAV nucleic acid and amino acid sequences. See also Table 1.

[0059] The capsid structures of autonomous parvoviruses and AAV are described in more detail in BERNARD N. FIELDS et al., VIROLOGY, Vol. 2, Chapters 69 and 70 (4th edition, Lippincott-Raven Publishers). See also the description of the crystal structures of AAV2 (Xie et al. (2002) Proc. Nat. Acad. Sci. 99: 10405-10); AAV4 (Padron et al. (2005) J. Virol. 79: 5047-58); AAV5 (Walters et al. (2004) J. Virol. 78: 3361-71); and CPV (Xie et al. (1996) J. Mol. Biol. 6: 497-520 and Tsao et al. (1991) Science 251: 1456-64).

[0060] As used herein, the term "tropism" refers to the preferential entry of a virus into certain cells or tissues, optionally followed by expression (e.g., transcription and optionally translation) in the cell of sequences carried by the viral genome, e.g., for a recombinant virus, expression of a heterologous nucleic acid of interest.

[0061] As used herein, "transduction" of a cell by a viral vector (eg, an AAV vector) means that the vector enters the cell and transfers genetic material into the cell by incorporation of nucleic acid into the viral vector and subsequent transfer via the viral vector into the cell.

[0062] Unless otherwise indicated, "efficient transduction" or "efficient tropism" or similar terms can be determined by reference to an appropriate positive or negative control (e.g., at least about 50%, 60%, 70%, 80%, 85%, 90%, 95% or more transduction or tropism, respectively, of a positive control, or at least about 110%, 120%, 150%, 200%, 300%, 500%, 1000% or more transduction or tropism, respectively, of a negative control).

[0063] Similarly, whether a virus "does not efficiently transduce" or "does not have an effective tropism" or similar terms for a target tissue can be determined by reference to an appropriate control. In specific embodiments, the viral vector does not efficiently transduce (i.e., does not have an effective tropism for) tissues outside the nervous system, such as the lungs, kidneys, gonads, and / or germ cells. In specific embodiments, undesirable tissue transduction is 20% or less, 10% or less, 5% or less, 1% or less, 0.1% or less of the level of transduction of the desired target tissue.

[0064] Unless otherwise indicated, the term "polypeptide" as used herein encompasses peptides and proteins.

[0065] A "polynucleotide" is a sequence of nucleotide bases, and may be RNA, DNA, or a DNA-RNA hybrid sequence (including both naturally occurring nucleotides and non-naturally occurring nucleotides), but in representative embodiments is a single-stranded or double-stranded DNA sequence.

[0066] As used herein, an "isolated" polynucleotide (e.g., "isolated DNA" or "isolated RNA") means a polynucleotide that is at least partially separated from at least some other components of a naturally occurring organism or virus, such as cellular or viral structural components or other polypeptides or nucleic acids with which the polynucleotide is normally found in association. In representative embodiments, the "isolated" polynucleotide is enriched at least about 10-fold, 100-fold, 1000-fold, 10,000-fold, or more compared to the starting material.

[0067] Likewise, an "isolated" polypeptide means a polypeptide that is at least partially separated from at least some other components of a naturally occurring organism or virus, such as cellular or viral structural components or other polypeptides or nucleic acids with which the polypeptide is normally found in association. In representative embodiments, an "isolated" polypeptide is enriched at least about 10-fold, 100-fold, 1000-fold, 10,000-fold, or more compared to the starting material.

[0068] A "nucleic acid," "nucleic acid molecule," or "nucleotide sequence" is a sequence of nucleotide bases, and may be RNA, DNA, or a DNA-RNA hybrid sequence (including both naturally occurring nucleotides and non-naturally occurring nucleotides), but is preferably a single-stranded or double-stranded DNA sequence.

[0069] As used herein, an "isolated" nucleic acid or nucleotide sequence (e.g., "isolated DNA" or "isolated RNA") means a nucleic acid or nucleotide sequence that is separated from or substantially free of at least some other components of a naturally occurring organism or virus, such as cellular or viral structural components or other polypeptides or nucleic acids with which the nucleic acid or nucleotide sequence is normally found.

[0070] Likewise, an "isolated" polypeptide means a polypeptide that is separated from or substantially free of at least some other components of a naturally occurring organism or virus, such as cellular or viral structural components or other polypeptides or nucleic acids with which the polypeptide is normally found.

[0071] "Isolated cells" refers to cells that are separated from other components with which they are normally associated in nature. For example, isolated cells can be cells in culture medium and / or cells in a pharmaceutically acceptable carrier of the present invention. Thus, isolated cells can be delivered to a subject and / or introduced into a subject. In some embodiments, isolated cells can be cells that are removed from a subject and manipulated ex vivo as described herein and then returned to the subject.

[0072] As used herein, "isolated" or "purified" (or grammatical equivalents) viral vectors or viral particles or viral particle populations means that the viral vectors or viral particles or viral particle populations are at least partially separated from at least some other components in the starting material. In representative embodiments, the "isolated" or "purified" viral vectors or viral particles or viral particle populations are enriched at least about 10-fold, 100-fold, 1000-fold, 10,000-fold or more compared to the starting material.

[0073] The term "endogenous" refers to components naturally found in the environment, ie, genes, nucleic acids, miRNAs, proteins, cells, or other native components expressed in a subject, as distinguished from components introduced (ie, "exogenous" components).

[0074] As used herein, the term "heterologous" refers to a nucleotide / polypeptide that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and / or genomic locus by deliberate human intervention.

[0075] A "heterologous nucleotide sequence" or "heterologous nucleic acid" is a sequence that does not naturally occur in a virus. Typically, a heterologous nucleic acid or nucleotide sequence comprises an open reading frame and / or non-translated RNA encoding a polypeptide.

[0076] A "therapeutic polypeptide" is a polypeptide that alleviates, reduces, prevents, delays and / or stabilizes symptoms caused by protein deletion or deficiency in a cell or subject, and / or otherwise confers a benefit to a subject (e.g., an anti-cancer effect or improved transplant survival or induction of an immune response).

[0077] The terms "treat," "treating," or "treatment of" (and grammatical variations thereof) mean to reduce, at least partially improve, or stabilize the severity of a subject's condition, and / or achieve some alleviation, relief, or reduction or stabilization of at least one clinical symptom, and / or there is a delay in progression of the disease or disorder.

[0078] By "substantially retaining" a property and / or maintaining a property that is "substantially the same" as a comparison (e.g., a control), it is meant that at least about 75%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of the property (e.g., activity or other measurable characteristic) is retained.

[0079] The terms "prevent," "preventing," and "prevention" (and grammatical variations thereof) refer to preventing and / or delaying the onset of, and / or reducing the severity of, the onset of one or more diseases, disorders, and / or clinical symptoms in a subject relative to what would occur in the absence of the methods of the present invention. Prevention can be complete, such as the complete absence of one or more diseases, disorders, and / or clinical symptoms. Prevention can also be partial, such that the onset and / or onset of one or more diseases, disorders, and / or clinical symptoms in a subject is substantially less severe than would occur in the absence of the present invention.

[0080] As used herein, a "therapeutically effective" or "effective" amount is an amount sufficient to provide some improvement or benefit to a subject. In other words, a "therapeutically effective" or "effective amount" is an amount that will provide some relief, alleviation, reduction, or stabilization of at least one clinical symptom of a subject. One skilled in the art will appreciate that the therapeutic effect need not be complete or curative, as long as some benefit is provided to the subject.

[0081] As used herein, a "prophylactically effective" amount is an amount sufficient to prevent and / or delay the onset of a disease, disorder, and / or clinical symptom in a subject and / or reduce and / or delay the severity of the onset of a disease, disorder, and / or clinical symptom in a subject relative to what would occur in the absence of the methods of the present invention. Those skilled in the art will appreciate that the level of prevention need not be complete, as long as some preventive benefit is provided to the subject.

[0082] The terms "nucleotide sequence of interest (NOI)", "heterologous nucleotide sequence" and "heterologous nucleic acid molecule" are used interchangeably herein and refer to a non-naturally occurring (e.g., engineered) nucleic acid sequence. Typically, a NOI, heterologous nucleic acid molecule or heterologous nucleotide sequence comprises an open reading frame encoding a polypeptide and / or a non-translated RNA of interest (e.g., for delivery to a cell and / or a subject).

[0083] As used herein, the term "viral vector," "vector," or "gene delivery vector" refers to a virus (e.g., AAV) particle used as a nucleic acid delivery vehicle and which contains a viral genome (e.g., viral DNA [vDNA]) and / or a replicon nucleic acid molecule packaged within the viral particle. Alternatively, in some cases, the term "vector" may be used to refer to the vector genome / vDNA alone.

[0084] As used herein, the term "vector" means any nucleic acid entity that can be amplified in a host cell. Therefore, a vector can be an autonomously replicating vector, that is, a vector that exists as an extrachromosomal entity, and its replication is independent of chromosomal replication, for example, a plasmid. Alternatively, a vector can be a vector that is integrated into the host cell genome when introduced into a host cell and replicates together with the chromosome into which it is integrated. The selection of a vector will often depend on the host cell into which it will be introduced. Vectors include, but are not limited to, plasmid vectors, phage vectors, viruses or cosmid vectors. A vector generally contains an origin of replication and at least one optional gene, that is, a gene encoding a product that can be easily detected or whose presence is a product that is essential for cell growth.

[0085] "rAAV vector genome" or "rAAV genome" is an AAV genome (i.e., vDNA) comprising at least one terminal repeat (e.g., two terminal repeats) and one or more heterologous nucleotide sequences. The rAAV vector generally requires only cis 145 base terminal repeats (TR) to generate the virus. All other viral sequences are dispensable and can be supplied in trans (Muzyczka, (1992) Curr. Topics Microbiol. Immunol. 158: 97). Typically, the rAAV vector genome will retain only minimal TR sequences to maximize the size of the transgene that can be effectively packaged by the vector. Structural and non-structural protein coding sequences can be provided in trans (e.g., from a vector such as a plasmid, or by stably integrating the sequence into a packaging cell). The rAAV vector genome optionally comprises two AAV TRs, which will generally be located at the 5' and 3' ends of the heterologous nucleotide sequence, but need not be adjacent thereto. TRs may be identical or different from each other.

[0086] A "rAAV particle" comprises a rAAV vector genome packaged within an AAV capsid.

[0087] The term "terminal repeat" or "TR" or "inverted terminal repeat (ITR)" includes any viral terminal repeat or synthetic sequence that forms a hairpin structure and functions as an inverted terminal repeat (i.e., mediates a desired function, such as replication, viral packaging, integration, and / or provirus rescue, etc.). The TR can be an AAV TR or a non-AAV TR. For example, a non-AAV TR sequence, such as sequences of other parvoviruses (e.g., canine parvovirus (CPV), parvovirus of mice (MVM), human parvovirus B-19) or any other viral sequence (e.g., an SV40 hairpin that acts as an SV40 origin of replication) can be used as a TR, which can be further modified by truncation, substitution, deletion, insertion, and / or addition. In addition, the TR can be partially or completely synthetic, such as the "double-D sequence" described in U.S. Pat. No. 5,478,745 to Samulski et al., which is incorporated herein by reference in its entirety.

[0088] "AAV terminal repeats" or "AAV TRs" can be from any AAV, including but not limited to serotype 1, serotype 2, serotype 3, serotype 4, serotype 5, serotype 6, serotype 7, serotype 8, serotype 9, serotype 10, serotype 11, serotype 12, serotype 13, or any other AAV now known or later discovered (see, e.g., Table 1). The AAV terminal repeats do not have to have native terminal repeat sequences (e.g., native AAV TR sequences can be altered by insertions, deletions, truncations, and / or missense mutations), as long as the terminal repeats mediate the desired function (e.g., replication, viral packaging, integration, and / or proviral rescue, etc.).

[0089] The AAV proteins VP1, VP2, and VP3 are capsid proteins that interact together to form the AAV capsid of icosahedral symmetry. VP1.5 is an AAV capsid protein described in U.S. Publication No. 2014 / 0037585, which is hereby incorporated by reference in its entirety.

[0090] The viral vectors of the invention may further be "targeted" viral vectors (e.g., having a directional tropism) and / or "hybrid" parvoviruses (i.e., wherein the viral TR and the viral capsid are from different parvoviruses) as described in International Patent Publication No. WO 00 / 28004 and Chao et al., (2000) Molecular Therapy 2:619, which are hereby incorporated by reference in their entireties.

[0091] The viral vector of the present invention may further be a duplex parvoviral particle as described in International Patent Publication No. WO 01 / 92551 (the disclosure of which is incorporated herein by reference in its entirety). Thus, in some embodiments, the double-stranded (duplex) genome may be packaged into the viral capsid of the present invention.

[0092] Additionally, the viral capsid or genomic elements may contain other modifications, including insertions, deletions, and / or substitutions.

[0093] As used herein, "chimeric" capsid proteins and / or "chimeric" or "modified" capsids refer to AAV capsid proteins or capsids that have been modified by replacing one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) amino acid residues in the amino acid sequence of the capsid protein relative to the wild type and inserting and / or deleting one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) amino acid residues in the amino acid sequence relative to the wild type. In some embodiments, complete or partial domains, functional regions, epitopes, etc. from one AAV serotype can replace the corresponding wild-type domains, functional regions, epitopes, etc. of different AAV serotypes in any combination to produce chimeric capsid proteins or modified capsids of the present invention. The production of chimeric capsid proteins or modified capsids can be carried out according to protocols well known in the art, and a large number of chimeric capsid proteins that can be included in the capsids of the present invention are described in the literature and herein.

[0094] As used herein, the term "amino acid" or "amino acid residue" encompasses any naturally occurring amino acid, modified forms thereof, and synthetic amino acids.

[0095] Naturally occurring L-amino acids are shown in Table 2.

[0096] Conservative amino acid substitutions are known in the art. In a particular embodiment, conservative amino acid substitutions include substitutions within one or more of the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and / or phenylalanine, tyrosine.

[0097] Alternatively, the amino acid may be a modified amino acid residue (non-limiting examples are shown in Table 3), and / or may be an amino acid modified by post-translational modification (e.g., acetylation, amidation, formylation, hydroxylation, methylation, phosphorylation or sulfatation).

[0098] In addition, the non-naturally occurring amino acid can be an "unnatural" amino acid as described by Wang et al., Annu Rev Biophys Biomol Struct. 35: 225-49 (2006). These unnatural amino acids can be advantageously used to chemically link the molecule of interest to the AAV capsid protein.

[0099] Compositions of the present invention

[0100] The present invention relates, in part, to compositions and methods for treating neurological disorders using modified chimeric AAV capsids.

[0101] AAV is a small (25 nm) non-enveloped virus that packages a linear single-stranded DNA genome. AAV can infect both dividing and quiescent cells and persists in an extrachromosomal state without integrating into the host cell's genome, although some integration of virus-borne genes into the host genome does occur in natural viruses.

[0102] The present invention relates to the design of chimeric adeno-associated virus (AAV) capsids with improved infectivity and enhanced tropism for nervous system tissues in vitro and in vivo compared to established AAV gene therapy systems.

[0103] Chimeras of the invention can be produced by replacing the amino acids identified herein (e.g., such as Figure 1 and Figure 2 In some embodiments, the amino acid residues of the present invention are substituted by introducing some (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, etc.) or all of them into the AAV VP1, VP2 and / or VP3 backbone. Not every identified amino acid needs to be substituted to produce the chimeric protein of the present invention. For example, in some embodiments, further substitutions and / or omissions of substitutions of about 1, 2, 3, 4 or 5 amino acids may be included in the production of the chimera of the present invention. The amino acid residue numbers provided in the amino acid sequences described herein are based on the corresponding unmodified (e.g., wild-type) VP1, VP2 and VP3 amino acid sequences of the corresponding AAV serotypes (e.g., AAV6, SEQ ID NO: 16, e.g., AAV9, SEQ ID NO: 21) as provided herein. However, it will be readily appreciated by those of ordinary skill in the art that equivalent amino acid positions in other AAV capsid protein amino acid sequences can be easily identified and used to produce the chimeric proteins of the present invention.

[0104] Thus, one aspect of the present invention provides a chimeric adeno-associated virus (AAV) capsid of a first serotype, comprising a VP1 capsid protein, a VP2 capsid protein and a VP3 capsid protein of the first serotype, wherein: a) the VP1 capsid protein and / or the VP2 capsid protein comprises one or more substitutions at the following amino acid positions: 24 (e.g., D24A), 41 (e.g., D41N), 125 (e.g., V125I), 129 (e.g., F129L), 135 (e.g., G135A), 147 (e.g., E147D), 159 (e.g., I159V), 162 (e.g., T162S), 164 (e.g., Q164V), 4K), 168 (e.g., K168R), 194 (e.g., T194A), 196 (e.g., A196S, A196T), 197 (e.g., A197S), 198 (e.g., V198L), 200 (e.g., P200S), 201 (e.g., T201G, T201N), 203 (e.g., M203V), 205 (e.g., S205A), 224 (e.g., A224S), 233 (e.g., T233Q) and / or 235 (e.g., L235M), and b) the VP3 capsid protein comprises one or more amino acid substitutions in the VP3 variable region (VR); wherein the numbering corresponds to SEQ ID NO: 16 (AAV6 VP1 / 2 / 3), and wherein the chimeric AAV capsid has enhanced neurotropic properties compared to the neurotropic properties of the corresponding wild-type AAV capsid of the first serotype.

[0105] The one or more amino acid substitutions in the VP3 VR may be in any VR (including but not limited to VR-I, VR-II, VR-III, VR-IV, VR-V, VR-VI, VR-VII, VR-VIII, the HI loop, and / or VR-IX). AAV VP3 VR regions are known in the art and include, for example Figure 2 For example, in some embodiments, one or more amino acid substitutions in a VP3 VR can be at amino acid positions 263 (e.g., A263E), 264 (e.g., S264T), 265 (e.g., T265A), 267 (e.g., A267S), and / or 268 (e.g., S268T) in VR-I, at amino acid positions 584 (e.g., L584F) and / or 598 (V598A) in VR-VIII, and / or at amino acid position 714 (e.g., T714S) in VR-IX.

[0106] In some embodiments, the one or more amino acid substitutions in the VP3 VR may comprise, consist essentially of, or consist of a complete or substantially complete exchange / replacement (e.g., all amino acid positions plus or minus one, two, three, four, or five or more positions) of the VR of the first AAV serotype, e.g., wherein the AAV VP3 VR substitutions comprise, consist essentially of, or consist of an amino acid sequence of a VR of a different AAV serotype and / or a synthetic VR in place of the VR of the first AAV serotype.

[0107] In some embodiments, the one or more amino acid substitutions in VP3 may include one or more substitutions in the VP3 capsid protein outside of the VR. For example, in some embodiments, the one or more substitutions in the VP3 capsid protein outside of the VR may include amino acid substitutions at the following positions: 272 (e.g., H272T), 311 (e.g., R311K), 313 (e.g., N313R), 640 (e.g., L640I), 642 (e.g., H642N), 646 (e.g., Q646L) and / or 722 (e.g., T722S).

[0108] In some embodiments, the enhanced neurotropic properties of the chimeric AAV capsids of the invention can be enhanced by about 5.0-fold or more, e.g., about 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20-fold or more, or any value or range therein, compared to the neurotropic properties of the corresponding wild-type AAV capsid. For example, in some embodiments, the chimeric AAV capsid of the invention can have a neurotropism that is enhanced by about 5-fold to about 10-fold, about 6-fold to about 25-fold, about 5.5-fold to about 18.5-fold, or about 7.5-fold to about 20-fold compared to the neurotropism of the corresponding AAV capsid, or an enhanced neurotropism of about 5-fold, about 9.5-fold, about 10-fold, about 17-fold, about 20-fold, about 25-fold compared to the neurotropism of the corresponding AAV capsid (e.g., AAV6 capsid, such as AAV9 capsid).

[0109] The first or more (e.g., second, third, fourth, etc.) AAV serotypes of the present invention can be any AAV serotype now known or later discovered, including but not limited to AAV type 1, AAV type 2, AAV type 3 (including types 3A and 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, AAV type 11, AAV type 12, AAV type 13, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, and those in Table 1. In some embodiments, the first AAV serotype can be AAV1, AAV2, AAV3, AAV4, AAV6, AAV7, AAV8, and / or AAV9. For example, in some embodiments, the first AAV serotype is AAV6. In some embodiments, the second AAV serotype can be AAV1, AAV2, AAV3, AAV4, AAV6, AAV7, AAV8, and / or AAV9. For example, in some embodiments, the second AAV serotype is AAV9.

[0110] In some embodiments, the chimeric AAV capsid of the invention may comprise a first AAV serotype that is AAV6; one or more amino acid substitutions in the VP1 and / or VP2 capsid proteins at the following amino acid positions: 24 (e.g., D24A), 129 (e.g., F129L), 194 (e.g., T194A), 196 (e.g., A196S), 197 (e.g., A197S), 200 (e.g., P200S), 201 (e.g., P202S), In some embodiments, the chimeric AAV capsids of the invention may further comprise one or more VP3 amino acid substitutions at the following positions: 311 (e.g., R311K), 313 (e.g., N313R), 640 (e.g., L640I), 646 (e.g., Q646L) and / or 722 (e.g., T722S).

[0111] In some embodiments, one or more amino acid substitutions in VP1 and / or VP2 may include D24A, F129L, T194A, A196S, A197S, P200S, T201G, M203V, S205A, A224S, and / or T233Q. In some embodiments, one or more amino acid substitutions in VP3 VR include VR-VIII L584F and / or V598A and / or VR-IX T714S. In some embodiments, additional VP3 amino acid substitutions may include R311K, N313R, L640I, Q646L, and / or T722S.

[0112] In some embodiments, the chimeric AAV capsid of the invention may comprise, consist essentially of, or consist of an amino acid sequence that is at least 70% identical (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO:1 (AAVH43).

[0113] SEQ ID NO: 1 AAVH43 VP1, VP2 and VP3

[0114]

[0115] In some embodiments, the chimeric AAV capsid of the invention may comprise a first AAV serotype that is AAV6; one or more substitutions in the VP1 and / or VP2 capsid proteins at the following amino acid positions: 125 (e.g., V125I), 129 (e.g., F129L), 135 (e.g., G135A), 147 (e.g., E147D), 159 (e.g., I159V), 162 (e.g., T162S), 164 (e.g., Q164K), 1 68 (e.g., K168R), 194 (e.g., T194A), 196 (e.g., A196T), 197 (e.g., A197S), 198 (e.g., V198L), 200 (e.g., P200S) and / or 201 (e.g., T201N); and one or more amino acid substitutions in the VP3 variable region (VR) at the following amino acid positions in VR-VIII: 584 (e.g., L584F) and / or 598 (e.g., V598A).

[0116] In some embodiments, one or more amino acid substitutions in VP1 and / or VP2 may include V125I, F129L, G135A, E147D, I159V, T162S, Q164K, K168R, T194A, A196T, A197S, V198L, P200S and / or T201N. In some embodiments, one or more amino acid substitutions in VP3 VR may include VR-VIII L584F and / or V598A.

[0117] In some embodiments, the chimeric AAV capsid of the invention may comprise, consist essentially of, or consist of an amino acid sequence that is at least 70% identical (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO:6 (AAVH48).

[0118] SEQ ID NO:6 AAVH48 VP1, VP2 and VP3

[0119]

[0120] In some embodiments, the chimeric AAV capsid of the invention may comprise a first AAV serotype that is AAV6; one or more substitutions in the VP1 and / or VP2 capsid proteins at the following amino acid positions: 41 (e.g., D41N), 129 (e.g., F129L), 168 (e.g., K168R), 201 (e.g., T201N) and / or 235 (e.g., L235M); and one or more amino acid substitutions in the VP3 variable region (VR) at the following amino acid positions in VR-I: 263 (e.g., A263E), 264 (e.g., S264T), 265 (e.g., T265A), 267 (e.g., A267S) and / or 268 (e.g., S268T). In some embodiments, the chimeric AAV capsid of the invention may further comprise one or more VP3 amino acid substitutions at the following positions: 272 (e.g., H272T) and / or 642 (e.g., H642N).

[0121] In some embodiments, one or more amino acid substitutions in VP1 and / or VP2 may include D41N, F129L, K168R, T201N and / or L235M. In some embodiments, one or more amino acid substitutions in VP3 VR may include VR-I A263E, S264T, T265A, A267S and / or S268T. In some embodiments, additional VP3 amino acid substitutions may include H272T and / or H642N.

[0122] In some embodiments, the chimeric AAV capsid of the invention may comprise, consist essentially of, or consist of an amino acid sequence that is at least 70% identical (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO:11 (AAVH67).

[0123] SEQ ID NO:11 AAVH67 VP1, VP2 and VP3

[0124]

[0125] It should be understood that these examples are not intended to be limiting, and any AAV serotype may be combined with any other AAV serotype in any combination of a first or more AAV serotypes.

[0126] Furthermore, as will be well understood by one of ordinary skill in the art, chimeric AAV capsids generated from VP1, VP2, and VP3 of corresponding AAV serotypes may be included in the methods and compositions of the present invention in any combination and / or in any ratio relative to each other.

[0127] Those of ordinary skill in the art can readily determine the amino acid residue positions that can be substituted to produce the desired chimeric AAV capsid based on the teachings herein and according to protocols well known in the art. The amino acid residue numbers provided in the amino acid sequences described herein are based on the reference sequence of the AAV6 wild-type VP1, VP2 and VP3 capsid protein amino acid sequence as provided herein (SEQ ID NO: 16 (AAV6 VP1, VP2 and VP3; Accession No. AAB95450.1), SEQ ID NO: 17 (AAV6 VP1 and VP2) and SEQ ID NO: 18 (AAV6 VP3). However, one of ordinary skill in the art will readily appreciate that equivalent amino acid positions in other AAV serotype sequences (e.g., including but not limited to AAD27757.1 (AAV1), YP_068409.1 (AAV5), AAC03780.1 (AAV2), AAC58045.1 (AAV4), NP_043941.1 (AAV3), AAB95450.1 (AAV6), YP_077178.1 (AAV7), YP_077180.1 (AAV8), AAS99264.1 (AAV9), AAO88201.1 (AAVrh10), and the amino acid sequences of any serotype of Table 1) can be readily identified and used to generate modified / chimeric AAV capsids of the present invention.

[0128] It should be understood that the above modifications provide multiple examples of how the amino acid sequences described herein can be obtained, and due to the degeneracy of amino acid codons, many other modifications can be made to the nucleotide sequences encoding the capsid or fragments thereof (e.g., VP1, VP2 and / or VP3) to obtain the desired amino acid sequence. The present invention provides additional non-limiting examples of nucleic acids and / or polypeptides of the present invention, which can be used in the compositions and methods described herein in the sequence section provided herein and in any substitutions described herein in the comparison section.

[0129] It will be apparent to those skilled in the art that the amino acid sequences of the modified / chimeric AAV capsids and capsid proteins of the present invention (including but not limited to SEQ ID NOs: 1-15) can be further modified to incorporate other modifications as known in the art to impart desired properties. As a non-limiting possibility, the capsid and / or capsid protein can be modified to incorporate a targeting sequence (e.g., a coagulation factor) or a sequence that facilitates purification and / or detection. For example, the capsid and / or capsid protein can be fused with all or part of the following to form a fusion protein: glutathione-S-transferase, maltose binding protein, heparin sulfate / heparan sulfate binding domain, poly-His, ligands and / or reporter proteins (e.g., green fluorescent protein, β-glucuronidase, β-galactosidase, luciferase, etc.), immunoglobulin Fc fragments, single-chain antibodies, hemagglutinin, c-myc, FLAG epitopes, etc. Methods for inserting targeting peptides into AAV capsids are known in the art (see, e.g., International Patent Publication No. WO 00 / 28004; Nicklin et al., (2001) Mol. Ther. 474-181; White et al., (2004) Circulation 109:513).

[0130] In some embodiments, the chimeric AAV capsids of the invention can be covalently linked, bound, or encapsidated with a compound selected from the group consisting of a DNA molecule (e.g., Cas9-plasmid), an RNA molecule (e.g., CRISPR RNA), a polypeptide, a carbohydrate, a lipid, a small organic molecule, and any combination thereof (e.g., CRISPR RNP).

[0131] The present invention also provides chimeric AAV capsids of the present invention and viral particles (i.e., virions) comprising the chimeric AAV capsids, wherein the viral particles package (i.e., encapsidate) vector genomes, optionally AAV vector genomes. In a specific embodiment, the present invention provides AAV particles comprising AAV capsids, wherein the AAV capsids comprise the AAV capsid proteins of the present invention, wherein the AAV capsids package the AAV vector genomes. The present invention also provides AAV particles comprising AAV capsids or AAV capsid proteins encoded by the modified nucleic acid capsid coding sequences of the present invention.

[0132] The chimeric capsid protein and capsid may further comprise any other modifications now known or later identified. It will be appreciated by those skilled in the art that for some AAV capsids, the corresponding modifications may be insertions and / or substitutions, depending on whether the corresponding amino acid position is partially or completely present in the virus, or completely absent. Similarly, when modifying an AAV other than, for example, AAV6, a particular amino acid position may be different from the position in AAV6. As discussed elsewhere herein, the corresponding amino acid positions will be apparent to those skilled in the art using well-known techniques.

[0133] Another aspect of the invention provides an AAV particle comprising: a chimeric AAV capsid of the invention; and an AAV vector genome; wherein the AAV capsid encapsidates the AAV vector genome. In some embodiments, the AAV vector genome may comprise a heterologous nucleic acid molecule. In some embodiments, the heterologous nucleic acid molecule may encode an antisense RNA, a microRNA, or an RNAi.

[0134] In a specific embodiment, the virosome is a recombinant vector comprising, for example, a heterologous nucleic acid (e.g., a target nucleic acid molecule) for delivery to a cell. Thus, the present invention can be used to deliver nucleic acids to cells in vitro, in vitro, and in vivo. In a representative embodiment, the recombinant vector of the present invention can be advantageously used to deliver or transfer nucleic acids to animal (e.g., mammalian) cells.

[0135] Heterologous molecules (e.g., nucleic acids, proteins, peptides, etc.) are defined as those not naturally found in AAV infection, e.g., those not encoded by the wild-type AAV genome. In addition, therapeutically useful molecules can be associated with transgenes to transfer the molecules into host target cells. Such related molecules can include DNA and / or RNA.

[0136] Any heterologous nucleotide sequence can be delivered by the viral vector of the present invention. The target nucleic acid includes a nucleic acid encoding a polypeptide, optionally a therapeutic (e.g., for medical or veterinary use) and / or immunogenic (e.g., for a vaccine) polypeptide. In some embodiments, the heterologous nucleic acid molecule can encode a polypeptide. In some embodiments, the heterologous nucleic acid molecule can encode a therapeutic polypeptide.

[0137] Therapeutic polypeptides include, but are not limited to, cystic fibrosis transmembrane regulator (CFTR), dystrophin (including the protein product of a dystrophin minigene or minigene, see, e.g., Vincent et al., (1993) Nature Genetics 5:130; U.S. Patent Publication No. 2003017131; Wang et al., (2000) Proc. Natl. Acad. Sci. USA 97:13714-9 [small dystrophin]; Harper et al., (2002) Nature Med. 8:253-61 [micro dystrophin]); agrin, laminin-α2, sarcoglycan (α, β, γ or δ), fukutin-related protein, myostatin propeptide, follistatin, dominant negative myostatin, angiogenic factors (e.g., VEGF, angiopoietin-1 or 2), anti-apoptotic factors (e.g., , heme oxygenase 1, TGF-β, inhibitors of pro-apoptotic signals such as caspases, proteases, kinases, death receptors [e.g., CD-095], cytochrome c release regulators, inhibitors of mitochondrial pore opening and swelling); activin type II soluble receptor, anti-inflammatory polypeptides such as dominant mutants of IκB, myosin, dystrophin-related protein (utrophin), dystrophin-related protein, antibodies or antibody fragments to myostatin or myostatin propeptide, cell cycle regulators, Rho kinase regulators such as Cethrin (which is a modified bacterial C3 exoenzyme) [available from BioAxone Therapeutics, Inc., Saint-Lauren, Quebec,Canada], BCL-xL, BCL2, XIAP, FLICEc-s, dominant negative caspase-8, dominant negative caspase-9, SPI-6 (see, e.g., U.S. Patent Application No. 20070026076), transcription factor PGC-α1, Pinch gene, ILK gene and thymosin β4 gene), coagulation factors (e.g., factor VIII, factor IX, factor X, etc.), erythropoietin, angiostatin, endostatin, catalase, tyrosine hydroxylase, intracellular and / or extracellular superoxide dismutase, leptin, LDL receptor, neprilysin, lipoprotein lipase, ornithine transcarbamylase, β-globin, α-globin , spectrin, α1-antitrypsin, methylcytosine binding protein 2, adenosine deaminase, hypoxanthine guanine phosphoribosyltransferase, β-glucocerebrosidase, sphingomyelinase, lysosomal hexosaminidase A, branched-chain ketoacid dehydrogenase, RP65 protein, cytokines (e.g., interferon α, interferon β, interferon-γ, interleukin-1 to interleukin-14, granulocyte-macrophage colony-stimulating factor, lymphotoxin, etc.), peptide growth factors, neurotrophic factors and hormones (e.g., somatotropin, insulin, insulin-like growth factor (including IGF-1 and IGF-2), GLP-1, platelet-derived growth factor, epidermal growth factor, fibroblast growth factor, nerve growth factor, etc.), factors, neurotrophic factors-3 and -4, brain-derived neurotrophic factor, glial-derived growth factor, transforming growth factor-α and -β, etc.), bone morphogenetic proteins (including RANKL and VEGF), lysosomal proteins, glutamate receptors, lymphokines, soluble CD4, Fc receptors, T cell receptors, ApoE, ApoC, protein phosphatase inhibitor 1 (I-1) inhibitor 1, phospholamban, serca2a, lysosomal acid α-glucosidase, α-galactosidase A, Barkct, β2-adrenergic receptor, β2-adrenergic receptor kinase (BARK), phosphoinositide 3 kinase (PI3 kinase), calsarcin, receptors (e.g., tumor necrosis growth factor-α soluble receptors), anti-inflammatory factors such as IRAP, Pim-1, PGC-1α, SOD-1, SOD-2, ECF-SOD, kallikrein, thymosin-β4, hypoxia-inducible transcription factor [HIF], angiogenic factors, S100A1, parvalbumin, adenylyl cyclase type 6, molecules that achieve knockdown of G protein-coupled receptor kinase type 2 such as truncated constitutively active bARKct; phospholamban inhibitory or dominant negative molecules such as phospholamban S16E, monoclonal antibodies (including single-chain monoclonal antibodies) or suicide gene products (e.g., thymidine kinase, cytosine deaminase, diphtheria toxin and tumor necrosis factor such as TNF-α) and any other polypeptides that have a therapeutic effect in a subject in need thereof.

[0138] The heterologous nucleotide sequence of coded polypeptide includes those of coding reporter polypeptide (for example, enzyme).Reporter polypeptide is known in the art and includes but is not limited to fluorescent protein (for example, EGFP, GFP, RFP, BFP, YFP or dsRED2), produces the enzyme of detectable product, such as luciferase (for example, from Gaussia, Renilla or Photinus), beta-galactosidase, beta-glucuronidase, alkaline phosphatase, and chloramphenicol acetyltransferase gene, or can directly detect albumen.Almost any albumen can be directly detected by using, for example, specific antibodies for the albumen. Additional markers (and related antibiotics) suitable for positive or negative selection of eukaryotic cells are disclosed in Sambrook and Russell (2001), Molecular Cloning, 3rd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, and Ausubel et al. (1992), Current Protocols in Molecular Biology, John Wiley & Sons (including regular updates).

[0139] Alternatively, the heterologous nucleic acid can encode a functional RNA, e.g., an antisense oligonucleotide, a ribozyme (e.g., as described in U.S. Pat. No. 5,877,022), an RNA that effects spliceosome-mediated trans-splicing (see Puttaraju et al., (1999) Nature Biotech. 17:246; U.S. Pat. No. 6,013,487; U.S. Pat. No. 6,083,702), an interfering RNA (RNAi) (including small interfering RNA (siRNA) that mediates gene silencing) (see Sharp et al., (2000) Science 287:2431), a microRNA or other non-translated "functional" RNA (such as a "guide" RNA) (Gorman et al., (1998) Proc. Nat. Acad. Sci. USA 95:4929; U.S. Pat. No. 5,869,248 to Yuan et al.), etc. Exemplary untranslated RNAs include RNAi or antisense RNAs to multidrug resistance (MDR) gene products (e.g., to treat tumors and / or for administration to the heart to prevent damage caused by chemotherapy), RNAi or antisense RNAs to myostatin (Duchenne or Becker muscular dystrophy), RNAi or antisense RNAs to VEGF or tumor immunogens (including, but not limited to, those tumor immunogens specifically described herein) (to treat tumors), RNAi or antisense oligonucleotides targeting mutated dystrophin (Duchenne or Becker muscular dystrophy), RNAi or antisense RNAs to the hepatitis B surface antigen gene (to prevent and / or treat hepatitis B infection), RNAi or antisense RNAs to the HIV tat and / or rev genes (to prevent and / or treat HIV), and / or RNAi or antisense RNAs to any other immunogen from a pathogen (to protect a subject from a pathogen) or RNAi or antisense RNAs to defective gene products (to prevent or treat disease). RNAi or antisense RNA to the above targets or any other targets can also be used as research reagents.

[0140] As is known in the art, antisense nucleic acid (e.g., DNA or RNA) and inhibitory RNA (e.g., microRNA and RNAi, such as siRNA or shRNA) sequences can be used to induce "exon skipping" in patients with muscular dystrophy caused by defects in the dystrophin gene. Thus, the heterologous nucleic acid may encode an antisense nucleic acid or inhibitory RNA that induces appropriate exon skipping. Those skilled in the art will appreciate that the specific method of exon skipping depends on the nature of the underlying defect in the dystrophin gene, and many such strategies are known in the art. Exemplary antisense nucleic acid and inhibitory RNA sequences target upstream branch points and / or downstream donor splice sites and / or internal splicing enhancer sequences of one or more dystrophin exons (e.g., exon 19 or 23). For example, in a particular embodiment, the heterologous nucleic acid encodes an antisense nucleic acid or inhibitory RNA directed to the upstream branch point and downstream splice donor site of exon 19 or 23 of the dystrophin gene. Such sequences can be incorporated into AAV vectors that deliver modified U7 snRNA and antisense nucleic acids or inhibitory RNAs (see, e.g., Goyenvalle et al., (2004) Science 306: 1796-1799). As another strategy, modified U1 snRNA can be incorporated into AAV vectors along with siRNA, microRNA, or antisense RNA complementary to upstream and downstream splice sites of dystrophin exons (e.g., exon 19 or 23) (see, e.g., Denti et al., (2006) Proc. Nat. Acad. Sci. USA 103: 3758-3763). In addition, antisense nucleic acids and inhibitory RNAs can target splicing enhancer sequences within exons 19, 43, 45, or 53 (see, e.g., U.S. Pat. No. 6,653,467; U.S. Pat. No. 6,727,355; and U.S. Pat. No. 6,653,466).

[0141] Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific manner. Ribozymes have specific catalytic domains that have endonuclease activity (Kim et al., (1987) Proc. Natl. Acad. Sci. USA 84:8788; Gerlach et al., (1987) Nature 328:802; Forster and Symons, (1987) Cell 49:211). For example, a large number of ribozymes accelerate phosphate transfer reactions with high specificity, often cleaving only one of several phosphates in an oligonucleotide substrate (Michel and Westhof, (1990) J. Mol. Biol. 216:585; Reinhold-Hurek and Shub, (1992) Nature 357:173). This specificity is due to the need for the substrate to bind to the internal guide sequence ("IGS") of the ribozyme via specific base pairing interactions prior to the chemical reaction.

[0142] Ribozyme catalysis has been observed primarily as part of sequence-specific cleavage / ligation reactions involving nucleic acids (Joyce, (1989) Nature 338:217). For example, U.S. Pat. No. 5,354,855 reports that certain ribozymes can act as endonucleases with sequence specificities greater than those of known ribonucleases and approaching those of DNA restriction enzymes. Therefore, sequence-specific ribozyme-mediated inhibition of nucleic acid expression may be particularly suitable for therapeutic applications (Scanlon et al., (1991) Proc. Natl. Acad. Sci. USA 88:10591; Sarver et al., (1990) Science 247:1222; Sioud et al., (1992) J. Mol. Biol. 223:831).

[0143] MicroRNA (mir) is a natural cell RNA molecule that can regulate the expression of multiple genes by controlling the stability of mRNA. Overexpression or reduction of specific microRNA can be used to treat dysfunction, and has been shown to be effective in many disease states and animal models of diseases (see, for example, Couzin, (2008) Science 319: 1782-4). Chimeric AAV can be used to deliver microRNA to cells, tissues, and subjects to treat hereditary and acquired diseases, or to enhance the functionality of certain tissues and promote their growth. For example, mir-1, mir-133, mir-206 and / or mir-208 can be used to treat heart and skeletal muscle diseases (see, for example, Chen et al., (2006) Genet.38: 228-33; van Rooij et al., (2008) Trends Genet.24: 159-66). MicroRNA can also be used to regulate the immune system after gene delivery (Brown et al., (2007) Blood 110: 4144-52).

[0144] As used herein, the term "antisense oligonucleotide" (including "antisense RNA") refers to a nucleic acid that is complementary to and specifically hybridizes to a specified DNA or RNA sequence. Antisense oligonucleotides and nucleic acids encoding antisense oligonucleotides can be prepared according to conventional techniques. See, for example, U.S. Patent No. 5,023,243 to Tullis; U.S. Patent No. 5,149,797 to Pederson et al.

[0145] Those skilled in the art will appreciate that an antisense oligonucleotide need not be completely complementary to a target sequence, as long as the degree of sequence similarity is sufficient to enable the antisense nucleotide sequence to specifically hybridize to its target (as defined above) and reduce the production of a protein product (e.g., by at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more).

[0146] To determine the specificity of hybridization, hybridization of such oligonucleotides to target sequences can be performed under reduced stringency, moderate stringency conditions, or even stringent conditions. Suitable conditions for achieving reduced, moderate, and stringent hybridization conditions are as described herein.

[0147] In other words, in certain embodiments, the antisense oligonucleotides of the invention have at least about 60%, 70%, 80%, 90%, 95%, 97%, 98% or more sequence identity to the complement of the target sequence and reduce the production of a protein product (as defined above). In some embodiments, the antisense sequence contains 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mismatches compared to the target sequence. Methods for determining percent identity of nucleic acid sequences are described in more detail elsewhere herein.

[0148] The length of the antisense oligonucleotide is not important, as long as it specifically hybridizes to the intended target and reduces the production of the protein product (as defined above), and can be determined according to routine procedures. Typically, the length of the antisense oligonucleotide is at least about 8, 10 or 12 or 15 nucleotides, and / or the length is less than about 20, 30, 40, 50, 60, 70, 80, 100 or 150 nucleotides.

[0149] RNA interference (RNAi) is another useful method for reducing the production of protein products (e.g., shRNA or siRNA). RNAi is a mechanism of post-transcriptional gene silencing, in which double-stranded RNA (dsRNA) corresponding to the target sequence of interest is introduced into a cell or organism, resulting in degradation of the corresponding mRNA. The mechanism by which RNAi achieves gene silencing has been reviewed in Sharp et al., (2001) Genes Dev 15:485-490; and Hammond et al., (2001) Nature Rev. Gen. 2:110-119). RNAi effects continue for multiple cell divisions to restore gene expression. Therefore, RNAi is a powerful method for targeted knockout or "knockdown" at the RNA level. RNAi has been shown to be successful in human cells (including human embryonic kidney and HeLa cells) (see, for example, Elbashir et al., Nature (2001) 411:494-8).

[0150] Initial attempts to use RNAi in mammalian cells led to antiviral defense mechanisms involving PKR-responsive dsRNA molecules (see, e.g., Gil et al., (2000) Apoptosis 5:107). It has since been demonstrated that short synthetic dsRNAs of approximately 21 nucleotides, termed "short interfering RNAs" (siRNAs), can mediate silencing in mammalian cells without triggering an antiviral response (see, e.g., Elbashir et al., Nature (2001) 411:494-8; Caplen et al., (2001) Proc. Nat. Acad. Sci. USA 98:9742).

[0151] RNAi molecules (including siRNA molecules) can be short hairpin RNA (shRNA; see Paddison et al., (2002), Proc. Nat. Acad. Sci. USA 99: 1443-1448), which are believed to be processed into 20-25-mer siRNA molecules in cells by the action of the RNase III-like enzyme Dicer. shRNAs generally have a stem-loop structure in which two inverted repeat sequences are separated by a short spacer sequence that loops out. There have been reports of shRNAs with loops ranging from 3 to 23 nucleotides in length. The loop sequence is generally not critical. Exemplary loop sequences include the following motifs: AUG, CCC, UUCG, CCACC, CTCGAG, AAGCUU, CCACACC, and UUCAAGAGA.

[0152] RNAi can further comprise a circular molecule comprising a sense region and an antisense region with two loop regions on either side to form a "dumbbell" shaped structure when a dsRNA is formed between the sense region and the antisense region. The molecule can be processed in vitro or in vivo to release a dsRNA portion, e.g., siRNA.

[0153] International Patent Publication WO 01 / 77350 describes vectors for bidirectional transcription to generate both sense and antisense transcripts of heterologous sequences in eukaryotic cells. This technology can be used to generate RNAi for use in accordance with the present invention.

[0154] Shinagawa et al., (2003) Genes Dev. 17: 1340 reported a method for expressing long dsRNA from a CMV promoter (pol II promoter), which is also applicable to tissue-specific pol II promoters. Similarly, Xia et al., (2002) Nature Biotech. 20: 1006 avoids poly (A) tailing and can be used in combination with tissue-specific promoters.

[0155] Methods for generating RNAi include chemical synthesis, in vitro transcription, digestion of long dsRNA by Dicer (in vitro or in vivo), in vivo expression from a delivery vector, and in vivo expression from a PCR-derived RNAi expression cassette (see, e.g., Tech Notes 10(3) "Five Ways to Produce siRNAs", from Ambion, Inc., Austin TX).

[0156] Guidelines for designing siRNA molecules are available (see, e.g., literature from Ambion, Inc., Austin TX, available at www.ambion.com). In a particular embodiment, the siRNA sequence has a G / C content of about 30-50%. In addition, if RNA polymerase III is used to transcribe the RNA, long stretches of greater than four T or A residues are generally avoided. An online siRNA target finder can be obtained, e.g., from Ambion, Inc. through the Whitehead Institute of Biomedical Research or from Dharmacon Research, Inc.

[0157] The antisense region of the RNAi molecule can be completely complementary to the target sequence, but need not be so, as long as it specifically hybridizes to the target sequence (as defined above) and reduces the production of the protein product (e.g., by at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more). In some embodiments, the hybridization of such oligonucleotides to the target sequence can be carried out under conditions of reduced stringency, moderate stringency, or even stringent conditions as defined above. In some embodiments, the antisense region contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mismatches compared to the target sequence. Mismatches are generally better tolerated at the end of the dsRNA than in the middle.

[0158] In certain embodiments, RNAi is formed by intermolecular complexation between two separate sense and antisense molecules. RNAi comprises a ds region formed by intermolecular base pairing between two separate strands. In other embodiments, RNAi comprises a ds region formed by intramolecular base pairing within a single nucleic acid molecule comprising both a sense region and an antisense region, typically as inverted repeats (e.g., shRNA or other stem-loop structures, or circular RNAi molecules). RNAi may further comprise a spacer between the sense region and the antisense region.

[0159] Typically, RNAi molecules are highly selective. If desired, one skilled in the art can easily eliminate candidate RNAi that may interfere with expression of nucleic acids other than the target by searching relevant databases to identify RNAi sequences that do not have substantial sequence homology with other known sequences, for example using BLAST (available at ncbi.nlm.nih.gov / BLAST). Kits for generating RNAi are commercially available, for example, from New England Biolabs, Inc. and Ambion, Inc.

[0160] The recombinant viral vector may also contain a heterologous nucleotide sequence that shares homology with a locus on the host chromosome and recombines with it. This method can be used to correct genetic defects in host cells.

[0161] The present invention also provides recombinant viral vectors expressing immunogenic polypeptides, for example for vaccination. The heterologous nucleic acid may encode any immunogen of interest known in the art, including but not limited to immunogens from human immunodeficiency virus, influenza virus, gag protein, tumor antigens, cancer antigens, bacterial antigens, viral antigens, etc. Alternatively, the immunogen may be presented in a viral capsid (e.g., incorporated therein) or tethered to a viral capsid (e.g., by covalent modification).

[0162] The use of parvovirus as a vaccine is known in the art (see, e.g., Miyamura et al., (1994) Proc. Nat. Acad. Sci. USA 91:8507; U.S. Pat. No. 5,916,563 to Young et al., U.S. Pat. No. 5,905,040 to Mazzara et al., U.S. Pat. No. 5,882,652, U.S. Pat. No. 5,863,541 to Samulski et al.; the disclosures of which are incorporated herein by reference in their entireties). The antigen may be presented in the viral capsid. Alternatively, the antigen may be expressed from a heterologous nucleic acid introduced into the genome of a recombinant vector.

[0163] The immunogenic polypeptide or immunogen can be any polypeptide suitable for protecting a subject from a disease, including but not limited to microbial diseases, bacterial diseases, protozoan diseases, parasitic diseases, fungal diseases, and viral diseases. For example, the immunogen can be an orthomyxovirus immunogen (e.g., an influenza virus immunogen, such as an influenza virus hemagglutinin (HA) surface protein or an influenza virus nucleoprotein gene, or an equine influenza virus immunogen) or a lentivirus immunogen (e.g., an equine infectious anemia virus immunogen, a simian immunodeficiency virus (SIV) immunogen, or a human immunodeficiency virus (HIV) immunogen, such as HIV or SIV envelope GP160 protein, HIV or SIV matrix / capsid protein, and HIV or SIV gag, pol, and env gene products). The immunogen can also be an arenavirus immunogen (e.g., a Lassa fever virus immunogen, such as a Lassa fever virus nucleocapsid protein gene and a Lassa fever envelope glycoprotein gene), a poxvirus immunogen (e.g., vaccinia, such as a vaccinia L1 or L8 gene), a flavivirus immunogen (e.g., a yellow fever virus immunogen or a Japanese encephalitis virus immunogen), a filovirus immunogen (e.g., an Ebola virus immunogen or a Marburg virus immunogen, such as NP and GP genes), a bunyavirus immunogen (e.g., RVFV, CCHF and SFS viruses), or a coronavirus immunogen (e.g., an infectious human coronavirus immunogen, such as a human coronavirus envelope glycoprotein gene, or a porcine transmissible gastroenteritis virus immunogen, or an avian infectious bronchitis virus immunogen, or a severe acute respiratory syndrome (SARS) immunogen, such as an S [S1 or S2], M, E or N protein or an immunogenic fragment thereof). The immunogen may further be a polio immunogen, a herpes immunogen (e.g., CMV, EBV, HSV immunogens) a mumps immunogen, a measles immunogen, a rubella immunogen, a diphtheria toxin or other diphtheria immunogen, a pertussis antigen, a hepatitis (e.g., hepatitis A, hepatitis B or hepatitis C) immunogen, or any other vaccine immunogen known in the art.

[0164] Alternatively, the immunogen can be any tumor or cancer cell antigen. Optionally, the tumor or cancer antigen is expressed on the surface of a cancer cell. Exemplary cancer and tumor cell antigens are described in A. Rosenberg, (1999) Immunity 10:281).Illustrative cancer and tumor antigens include, but are not limited to, BRCA1 gene products, BRCA2 gene products, gp100, tyrosinase, GAGE-1 / 2, BAGE, RAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE, SART-1, PRAME, p15, melanoma tumor antigens (Kawakami et al., (1994) Proc. Natl. Acad. Sci. USA 91:3515; Kawakami et al., (1994) J. Exp. Med., 180:347; Kawakami et al., (1994) Cancer Res.54:3124), including MART-1 (Coulie et al., (1991) J. Exp. Med. 180:35), gp100 (Wick et al., (1988) J. Cutan. Pathol. 4:201) and MAGE antigens (MAGE-1, MAGE-2 and MAGE-3) (Vander Bruggen et al., (1991) Science, 254:1643), CEA, TRP-1; TRP-2; P-15 and tyrosinase (Brichard et al., (1993) J. Exp. Med. 178:489); HER-2 / neu gene product (U.S. Pat. No. 4,968,603); CA125; HE4; LK26; FB5 (endosialin); TAG 72; AFP; CA19-9; NSE; DU-PAN-2; CA50; Span-1; CA72-4; HCG; STN (sialyl Tn antigen); c-erbB-2 protein; PSA; L-CanAg; estrogen receptor; milk fat globulin; p53 tumor suppressor protein (Levine, (1993) Ann. Rev. Biochem. 62:623); mucin antigens (International Patent Publication WO 90 / 05142); telomerase; nuclear matrix protein; prostatic acid phosphatase; papillomavirus antigens; and antigens associated with the following cancers: melanoma, adenocarcinoma, thymoma, sarcoma, lung cancer, liver cancer, colorectal cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma Cancers of the lung, lung, ovarian, uterine, pancreatic, cervical, bladder, kidney, stomach, esophagus, head and neck, and the like (see, e.g., Rosenberg, (1996) Annu. Rev. Med. 47:481-91).

[0165] The present invention further provides a composition, which can be a pharmaceutical formulation (eg, a pharmaceutical composition) comprising the viral vector or AAV particle of the present invention and a pharmaceutically acceptable carrier.

[0166] Alternatively, the heterologous nucleotide sequence may encode any polypeptide that is desired to be produced in cells in vitro, ex vivo or in vivo. For example, a viral vector may be introduced into cultured cells and the expressed protein product isolated therefrom.

[0167] The present invention further provides nucleic acid molecules encoding the chimeric AAV capsids of the present invention.

[0168] Those skilled in the art will appreciate that one or more heterologous nucleic acids of interest may be operably associated with appropriate control sequences. For example, a heterologous nucleic acid may be operably associated with expression control elements such as transcription / translation control signals, replication origins, polyadenylation signals, internal ribosome entry sites (IRES), promoters, enhancers, etc.

[0169] Those skilled in the art will further appreciate that a variety of promoter / enhancer elements may be used, depending on the desired level and tissue-specific expression. Promoters / enhancers may be constitutive or inducible, depending on the desired expression pattern. Promoters / enhancers may be native or foreign, and may be native or synthetic sequences. Foreign is intended to mean that the transcription initiation region is not found in the wild-type host into which the transcription initiation region is introduced.

[0170] The promoter / enhancer element may be native to the target cell or native to the heterologous nucleic acid sequence to be treated. The promoter / enhancer element is generally selected so that it will function in one or more target cells of interest. In representative embodiments, the promoter / enhancer element is a mammalian promoter / enhancer element. The promoter / enhancer element may be constitutive or inducible.

[0171] Inducible expression control elements are generally used in those applications where it is desired to provide regulation for the expression of one or more heterologous nucleic acid sequences. The inducible promoter / enhancer element for gene delivery can be a tissue-specific or tissue-preferred promoter / enhancer element, and includes muscle-specific or preferred (including cardiac muscle, skeletal muscle and / or smooth muscle) promoter / enhancer element, neural tissue-specific or preferred (including brain-specific) promoter / enhancer element, eye (including retina-specific and cornea-specific) promoter / enhancer element, liver-specific or preferred promoter / enhancer element, bone marrow-specific or preferred promoter / enhancer element, pancreas-specific or preferred promoter / enhancer element, spleen-specific or preferred promoter / enhancer element and lung-specific or preferred promoter / enhancer element. In one embodiment, CNS cell-specific or CNS cell-preferred promoters are used. Examples of neuron-specific or preferred promoters include but are not limited to neuron-specific enolase, synaptophysin and MeCP2. Examples of astrocyte-specific or preferred promoters include but are not limited to glial fibrillary acid protein and S100β. Examples of ependymal cell-specific or preferred promoters include, but are not limited to, wdr16, Foxj1, and LRP2. Examples of microglia-specific or preferred promoters include, but are not limited to, F4 / 80, CX3CR1, and CD11b. Examples of oligodendrocyte-specific or preferred promoters include, but are not limited to, myelin basic protein, cyclic nucleotide phosphodiesterase, proteolipid protein, Gtx, and Sox10. The use of CNS cell-specific or preferred promoters can increase the specificity achieved by the chimeric AAV vector by further limiting the expression of heterologous nucleic acids to the CNS. Other inducible promoter / enhancer elements include hormone-inducible elements and metal-inducible elements. Exemplary inducible promoter / enhancer elements include, but are not limited to, Tet on / off elements, RU486 inducible promoters, ecdysone-inducible promoters, rapamycin-inducible promoters, and metallothionein promoters.

[0172] In embodiments where one or more heterologous nucleic acid sequences are transcribed and then translated in the target cell, specific initiation signals are generally employed to efficiently translate the inserted protein coding sequences. These exogenous translation control sequences (which may include the ATG initiation codon and adjacent sequences) may have a variety of origins, both natural and synthetic.

[0173] In other embodiments, the nucleic acid sequence encoding a variant capsid or capsid protein of the invention has at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity to the nucleic acid sequence encoding the amino acid sequence of SEQ ID NOs: 1-15, and optionally encodes a variant capsid or capsid protein that substantially retains at least one property of the capsid or capsid protein of the amino acid sequence of SEQ ID NOs: 1-15.

[0174] As known in the art, many different programs can be used to identify whether a nucleic acid or polypeptide has sequence identity with a known sequence. As used herein, percent identity means that when using BLASTN and another nucleic acid (or its complementary strand) optimal alignment (with appropriate nucleotide insertion or deletion), a nucleic acid or its fragment shares a specified percent identity with another nucleic acid. In order to determine the percent identity between two different nucleic acids, the BLASTN program "BLAST 2 sequences" will be used to determine the percent identity. The program can be obtained from the National Center for Biotechnology Information (NCBI) via the Internet for public use (Altschul et al., (1997) Nucleic Acids Res. 25 (17): 3389-3402). To be used is any combination of the following that yields the highest calculated percent identity (calculated as follows), with default parameters shown in parentheses: Program --blastn Matrix --0BLOSUM62 Match Reward --0 or 1 (1) Mismatch Penalty --0, -1, -2 or -3 (-2) Open Gap Penalty --0, 1, 2, 3, 4 or 5 (5) Extension Gap Penalty --0 or 1 (1) Gap x_dropoff --0 or 50 (50) Expect --10.

[0175] When referring to a polypeptide, the identity or similarity percentage indicates that when compared to another protein or a portion thereof over a common length, the polypeptide in question exhibits a specified identity or similarity percentage as determined using BLASTP. This program can also be obtained from the National Center for Biotechnology Information (NCBI) via the Internet for public use (Altschul et al., (1997) Nucleic Acids Res. 25 (17): 3389-3402). Sequence analysis software is typically used to measure the identity or similarity percentage of a polypeptide. See, for example, the sequence analysis software package of Genetics Computer Group, University of Wisconsin Biotechnology Center, 910 University Avenue, Madison, Wis. 53705. Protein analysis software uses homology measurements assigned to various substitutions, deletions, and other modifications to match similar sequences. Conservative substitutions generally include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

[0176] The invention also provides chimeric AAV particles comprising an AAV capsid and an AAV genome, wherein the AAV genome "corresponds to" (i.e., encodes) an AAV capsid. Also provided are collections or libraries of such chimeric AAV particles, wherein the collections or libraries comprise 2 or more, 10 or more, 50 or more, 10 ... 4 or more, 10 5 or more, or 10 6 or more different sequences.

[0177] The present invention further encompasses "empty" capsid particles (i.e., in the absence of a vector genome) comprising, consisting of, or essentially consisting of a chimeric AAV capsid protein of the present invention. The chimeric AAV capsid of the present invention can be used as a "capsid vehicle", as described in U.S. Patent No. 5,863,541. Molecules that can be covalently linked to, bound to, or packaged by the viral capsid and transferred to cells include DNA, RNA, lipids, carbohydrates, polypeptides, small organic molecules, or combinations thereof. In addition, molecules can be associated (e.g., "tethered") to the outside of the viral capsid to transfer the molecule to a host target cell. In one embodiment of the present invention, the molecule is covalently linked (i.e., conjugated or chemically coupled) to the capsid protein. Methods of covalently linking molecules are known to those skilled in the art.

[0178] The viral capsids of the present invention can also be used to generate antibodies against novel capsid structures.As yet another alternative, foreign amino acid sequences can be inserted into viral capsids to present antigens to cells, for example, for administration to subjects to generate an immune response to foreign amino acid sequences.

[0179] The present invention also provides nucleic acids (e.g., isolated nucleic acids) encoding chimeric viral capsids and chimeric capsid proteins of the present invention. Further provided are vectors comprising nucleic acids of the present invention and cells (in vivo or in culture) comprising nucleic acids and / or vectors. Such nucleic acids, vectors, and cells can be used, for example, as reagents (e.g., auxiliary constructs or packaging cells) for producing viral vectors as described herein.

[0180] In some embodiments, the vector of the present invention can be a plasmid, a phage, a viral vector, a bacterial artificial chromosome, or a yeast artificial chromosome.

[0181] In some embodiments, the viral vector of the present invention can be an AAV vector, an adenovirus vector, a herpes virus vector, a lentivirus vector, an alphavirus vector, or a baculovirus vector (e.g., an AAV particle, an adenovirus particle, a herpes virus particle, a lentivirus particle, an alphavirus particle, a baculovirus particle, etc.).

[0182] In some embodiments, the nucleic acid encoding the chimeric AAV capsid protein further comprises an AAV rep coding sequence. For example, the nucleic acid can be a helper construct for producing a viral stock.

[0183] In another aspect of the invention, the chimeric / modified AAV capsids and vectors of the invention are completely or nearly completely detargeted vectors, which can be further modified to a desired tropism profile for targeting one or more peripheral organs or tissues.

[0184] The invention also provides packaging cells that stably contain the nucleic acid of the invention. For example, the nucleic acid may be stably incorporated into the genome of the cell or may be stably maintained in episomal form (eg, an "EBV-based nuclear episome").

[0185] The nucleic acid can be incorporated into a delivery vector (such as a viral delivery vector). For example, the nucleic acid of the invention can be packaged in an AAV particle, an adenovirus particle, a herpes virus particle, a baculovirus particle, or any other suitable viral particle. In addition, the nucleic acid can be operably associated with a promoter element. Promoter elements are described in more detail herein.

[0186] Further provided are pharmaceutical formulations comprising the AAV particles, nucleic acid molecules and / or vectors of the invention in a pharmaceutically acceptable carrier.

[0187] In some embodiments, the present invention provides a pharmaceutical composition comprising a viral vector of the present invention in a pharmaceutically acceptable carrier, and optionally other pharmaceutical agents, pharmaceutical agents, stabilizers, buffers, carriers, adjuvants, diluents, etc. For injection, the carrier is typically a liquid. For other methods of administration, the carrier can be solid or liquid. For inhalation administration, the carrier will be inhalable and will preferably be in the form of solid or liquid microparticles.

[0188] "Pharmaceutically acceptable" means a material that is not toxic or otherwise undesirable, ie, the material can be administered to a subject without causing any undesirable biological effect.

[0189] Method for preparing the present invention

[0190] The present invention further provides methods for producing viral capsids and / or viral particles of the present invention. In some embodiments, the present invention provides methods for producing recombinant AAV particles comprising AAV capsids, the method comprising: providing / introducing nucleic acid molecules of the present invention, AAV rep coding sequences, the AAV vector genome, and auxiliary functions for generating productive AAV infections to cells in vitro under conditions where the assembly of the recombinant AAV particles comprising the AAV capsid and the AAV vector genome containing heterologous nucleic acid molecules can occur. Provide templates and AAV replication and capsid sequences under conditions that allow the production of recombinant viral particles comprising templates packaged in capsids in cells. The method may further include the step of collecting viral particles from cells. Viral particles can be collected from culture medium and / or by lysing cells. AAV particles produced by such methods are further provided herein.

[0191] The cells are typically cells that are permissive for AAV viral replication. Any suitable cell known in the art may be employed, such as mammalian cells. Also suitable are trans-complementing packaging cell lines that provide the functions missing from the replication-defective helper virus, for example, 293 cells or other E1a trans-complementing cells.

[0192] AAV replication and capsid sequences can be provided by any method known in the art. Current protocols typically express AAV rep / cap genes on a single plasmid. AAV replication and packaging sequences do not need to be provided together, although this may be convenient. AAV rep and / or cap sequences can be provided by any viral vector or non-viral vector. For example, the rep / cap sequence can be provided by a hybrid adenovirus or herpes virus vector (e.g., in the E1a or E3 region of an indel adenovirus vector). EBV vectors can also be used to express AAV cap and rep genes. One advantage of this method is that EBV vectors are episomal, but will maintain a high copy number throughout continuous cell divisions (i.e., stably integrated into cells as extrachromosomal elements, referred to as EBV-based nuclear episomes).

[0193] As a further alternative, the rep / cap sequences may be stably carried within the cell (either episomal or integrated).

[0194] Typically, the AAV rep / cap sequences will not be flanked by AAV packaging sequences (e.g., AAV ITRs) to prevent rescue and / or packaging of these sequences.

[0195] The template (e.g., rAAV vector genome) can be provided to the cell using any method known in the art. For example, the template can be supplied by a non-viral (e.g., plasmid) or viral vector. In a specific embodiment, the template is supplied by a herpes virus or adenovirus vector (e.g., inserted into the E1a or E3 region of a missing adenovirus). As another illustration, Palombo et al., (1998) J. Virol. 72: 5025 describes a baculovirus vector carrying a reporter gene flanked by AAV ITRs. EBV vectors can also be used to deliver templates, as described above for the rep / cap gene.

[0196] In another representative embodiment, the template is provided by a replicative rAAV virus. In other embodiments, the AAV provirus is stably integrated into the chromosome of the cell.

[0197] In order to obtain maximum viral titers, cells are usually provided with helper virus functions (e.g., adenovirus or herpes virus) that are essential for productive AAV infection. Helper virus sequences necessary for AAV replication are known in the art. Typically, these sequences are provided by helper adenovirus or herpes virus vectors. Alternatively, adenovirus or herpes virus sequences can be provided by another non-viral or viral vector, for example, as a non-infectious adenovirus miniplasmid carrying all the helper genes required for effective AAV production, as described by Ferrari et al., (1997) Nature Med. 3: 1295 and U.S. Patent Nos. 6,040,183 and 6,093,570.

[0198] In addition, helper virus functions can be provided by packaging cells with helper genes integrated into the chromosome or maintained as stable extrachromosomal elements. In representative embodiments, the helper virus sequences cannot be packaged into AAV virions, for example, they are not flanked by AAV ITRs.

[0199] Those skilled in the art will appreciate that it may be advantageous to provide AAV replication and capsid sequences and helper virus sequences (e.g., adenovirus sequences) on a single helper construct. The helper construct may be a non-viral construct or a viral construct, but is optionally a hybrid adenovirus or hybrid herpes virus comprising the AAV rep / cap gene.

[0200] In a specific embodiment, the AAV rep / cap sequence and the adenovirus helper sequence are supplied by a single adenovirus helper vector. The vector further contains a rAAV template. The AAV rep / cap sequence and / or the rAAV template can be inserted into a deletion region (e.g., E1a or E3 region) of an adenovirus.

[0201] In yet another embodiment, the AAV rep / cap sequences and adenoviral helper sequences are supplied by a single adenoviral helper vector. The rAAV template is provided as a plasmid template.

[0202] In another illustrative embodiment, the AAV rep / cap sequence and the adenovirus helper sequence are provided by a single adenovirus helper vector, and the rAAV template is integrated into the cell as a provirus. Alternatively, the rAAV template is provided by an EBV vector maintained in the cell as an extrachromosomal element (e.g., as an "EBV-based nuclear episome," see Margolski, (1992) Curr. Top. Microbiol. Immun. 158: 67).

[0203] In yet another exemplary embodiment, the AAV rep / cap sequence and the adenoviral helper sequence are provided by a single adenoviral helper sequence. The rAAV template is provided as a separate replicating viral vector. For example, the rAAV template can be provided by a rAAV particle or a second recombinant adenoviral particle.

[0204] According to the aforementioned method, the hybrid adenoviral vector generally comprises adenoviral 5' and 3' cis sequences (i.e., adenoviral terminal repeats and PAC sequences) sufficient for adenoviral replication and packaging. The AAV rep / cap sequence and rAAV template (if present) are embedded in the adenoviral backbone and are flanked by 5' and 3' cis sequences so that these sequences can be packaged into adenoviral capsids. As described above, in representative embodiments, the adenoviral helper sequence and the AAV rep / cap sequence are not flanked by AAV packaging sequences (e.g., AAV ITRs) so that these sequences are not packaged into AAV virions.

[0205] Herpes viruses can also be used as helper viruses in AAV packaging methods. Hybrid herpes viruses encoding one or more AAV rep proteins can advantageously facilitate more scalable AAV vector production schemes. Hybrid herpes simplex virus type I (HSV-1) vectors expressing AAV-2 rep and cap genes have been described (Conway et al., (1999) Gene Therapy 6:986 and WO 00 / 17377, the disclosures of which are incorporated herein in their entirety).

[0206] As yet another alternative, the viral vectors of the invention can be produced in insect cells using baculovirus vectors to deliver the rep / cap genes and the rAAV template as described by Urabe et al., (2002) Human Gene Therapy 13: 1935-43.

[0207] Other methods of producing AAV use stably transformed packaging cells (see, e.g., U.S. Pat. No. 5,658,785).

[0208] AAV vector stock solutions free of contaminating helper viruses can be obtained by any method known in the art. For example, AAV and helper viruses can be easily distinguished based on size. AAV can also be separated from helper viruses based on affinity for heparin substrates (Zolotukhin et al., (1999) Gene Therapy 6:973). In a representative embodiment, a deleted replication-deficient helper virus is used so that any contaminating helper virus does not have the ability to replicate. As another alternative, an adenovirus helper lacking late gene expression can be used because only adenovirus early gene expression is required to mediate the packaging of the AAV virus. Adenovirus mutants defective in late gene expression are known in the art (e.g., ts100K and ts149 adenovirus mutants).

[0209] The packaging methods of the present invention can be used to produce high titer viral particle stocks. In certain embodiments, the viral stock has at least about 10 5 Transduction units (tu) / ml, at least about 10 6tu / ml, at least about 10 7 tu / ml, at least about 10 8 tu / ml, at least about 10 9 tu / ml or at least about 10 10 Titer of tu / ml.

[0210] The novel capsid proteins and capsid structures can be used to generate antibodies, for example for diagnostic or therapeutic use or as research reagents. Therefore, the present invention also provides antibodies against the novel capsid proteins and capsids of the present invention.

[0211] The term "antibody" as used herein refers to all types of immunoglobulins, including IgG, IgM, IgA, IgD and IgE. Antibodies can be monoclonal or polyclonal and can be species of any origin, including (for example) mice, rats, rabbits, horses, goats, sheep or humans, or can be chimeric antibodies. See, for example, Walker et al., Mol. Immunol. 26, 403-11 (1989). Antibodies can be recombinant monoclonal antibodies produced, for example, according to the methods disclosed in U.S. Patent No. 4,474,893 or U.S. Patent No. 4,816,567. Antibodies can also be chemically constructed, for example, according to the methods disclosed in U.S. Patent No. 4,676,980.

[0212] Antibody fragments included within the scope of the present invention include, for example, Fab, F(ab')2 and Fc fragments, and corresponding fragments obtained from antibodies other than IgG. Such fragments can be produced by known techniques. For example, F(ab')2 fragments can be produced by pepsin digestion of antibody molecules, and Fab fragments can be produced by reducing the disulfide bridges of F(ab')2 fragments. Alternatively, Fab expression libraries can be constructed to allow rapid and easy identification of monoclonal Fab fragments with desired specificity (Huse et al., (1989) Science 254, 1275-1281).

[0213] The polyclonal antibodies can be produced according to known procedures by immunizing a suitable animal (eg, rabbit, goat, etc.) with an antigen to which a monoclonal antibody against a target binds, collecting immune serum from the animal, and isolating polyclonal antibodies from the immune serum.

[0214] Monoclonal antibodies can be produced in hybridoma cell lines according to the techniques of Kohler and Milstein, (1975) Nature 265, 495-97. For example, a solution containing an appropriate antigen can be injected into mice, and after a sufficient time, the mice are killed and spleen cells are obtained. Splenocytes are then immortalized by fusing splenocytes with myeloma cells or lymphoma cells (usually in the presence of polyethylene glycol) to produce hybridoma cells. Hybridoma cells are then cultured in a suitable culture medium, and the supernatant is screened for monoclonal antibodies with the desired specificity. Monoclonal Fab fragments can be produced in Escherichia coli by recombinant techniques known to those skilled in the art. See, for example, W. Huse, (1989) Science 246, 1275-81.

[0215] Antibodies specific for the target polypeptide can also be obtained by phage display technology known in the art.

[0216] Various immunoassays can be used to screen to identify antibodies with desired specificity. Many protocols for competitive binding or immunoradiometric assays using polyclonal or monoclonal antibodies with determined specificity are well known in the art. Such immunoassays generally involve measuring the complex formation between an antigen and its specific antibody (e.g., antigen / antibody complex formation). Dual-site, monoclonal immunoassays and competitive binding assays utilizing monoclonal antibodies reactive to two non-interfering epitopes can be used.

[0217] Can be according to known technology, antibody and solid support (for example, by the bead, plate, slide or hole formed by material such as latex or polystyrene) be conjugated. Can be according to known technology, antibody directly or indirectly with detectable group such as radiolabel (for example, 35S, 125I, 131I), enzyme label (for example, horseradish peroxidase, alkaline phosphatase) and fluorescent label (for example, fluorescein) be conjugated. In the method for the present invention, the formation of antibody / antigen complex can be determined by detecting, for example, precipitation, agglutination, flocculation, radioactivity, color development or color change, fluorescence, luminescence, etc., as well known in the art.

[0218] Another aspect of the invention provides AAV particles produced by the methods described herein.

[0219] Using the method of the present invention

[0220] The present invention also relates to methods for delivering heterologous nucleotide sequences to preferred tissues (e.g., nervous system). The viral vectors of the present invention can be used to deliver the target nucleotide sequence to cells in vitro, for example, to produce polypeptides or nucleic acids in vitro or for ex vivo gene therapy. The vector can additionally be used in methods for delivering nucleotide sequences to subjects in need, for example, to express therapeutic or immunogenic polypeptides or nucleic acids. In this way, the polypeptides or nucleic acids can therefore be produced in the subject. The subject may need the polypeptide or nucleic acid because the subject has a defect in the polypeptide, or because the production of the polypeptide or nucleic acid in the subject can be used as a method of treatment or otherwise and as further explained below, to confer some therapeutic effects.

[0221] In certain embodiments, the vectors can be used to express polypeptides or nucleic acids that provide a beneficial effect to the nervous system, for example, to deliver a therapeutic gene product and / or otherwise treat a neurological disorder, such as, but not limited to, Parkinson's disease, Huntington's disease, Rett syndrome, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), epilepsy, Alzheimer's disease (GDF; neprilysin), Batten disease (ceroid lipofuscinosis neuronal protein [CLN] 1-10), Friedreich's ataxia (FRDA, frataxin gene [FXN]), brain trauma, spinal cord injury (SCI), ischemic and hypoxic CNS diseases, brain and spinal cord tumors, or any combination thereof. Thus, the ability to target a vector to the nervous system may be particularly useful for treating diseases or disorders involving neurological dysfunction.

[0222] Therefore, one aspect of the invention provides a method for delivering a nucleic acid molecule to a neural cell, the method comprising contacting the neural cell with an AAV particle, nucleic acid molecule, vector, cell and / or pharmaceutical formulation of the invention. The neural cell can be any cell of the nervous system, including but not limited to cells of the peripheral and central nervous systems, for example, brain cells, such as neurons, oligodendrocytes, glial cells, microglia, astrocytes, for example, spinal cord, such as cervical, thoracic, lumbar, sacral neurons and / or dorsal root ganglion (DRG) neurons.

[0223] Further provided is a method of delivering a nucleic acid molecule (e.g., a target nucleic acid molecule) to a neural cell of a mammalian subject, the method comprising: administering to a mammalian subject an effective amount of an AAV particle, nucleic acid molecule, vector, and / or pharmaceutical formulation of the invention, thereby delivering the nucleic acid molecule to the neural cell of the mammalian subject. In some embodiments, the mammalian subject is a human.

[0224] Yet another aspect of the invention provides a method for treating a condition in a mammalian subject in need thereof, wherein the condition can be treated by expressing a nucleic acid molecule encoding a therapeutic product in the nervous system of the subject, the method comprising administering to the mammalian subject a therapeutically effective amount of the AAV particles, nucleic acids, vectors and / or pharmaceutical formulations of the invention under conditions such that the nucleic acid molecule encoding the therapeutic product is expressed in the nervous system (e.g., CNS and / or PNS), thereby treating the condition.

[0225] The disorders of the present invention may include any related disorder of the nervous system, e.g., a CNS disorder, e.g., a PNS disorder. In some embodiments, the disorder may be Parkinson's disease, Huntington's disease, Rett syndrome, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), epilepsy, Alzheimer's disease (GDF; neprilysin), Batten disease (ceroid lipofuscinosis neuronal protein [CLN] 1-10), Friedreich's ataxia (FRDA, Friedreich's ataxia gene [FXN]), brain trauma, spinal cord injury (SCI), ischemic and hypoxic CNS diseases, brain and spinal cord tumors, or any combination thereof.

[0226] In some embodiments, AAV particles can be delivered to the nervous system by routes of administration including, but not limited to, intrathecal, intracerebral, intraparenchymal, intracerebroventricular, intranasal, intraauricular, intraocular or periocular delivery, intravenous delivery (IV), or any combination thereof.

[0227] In some embodiments, the AAV particles can be delivered or administered to the gray matter of a subject. In some embodiments, the AAV particles can be delivered or administered to the spinal cord (e.g., cervical, thoracic, lumbar, and / or sacral spinal cord regions).

[0228] Generally, the viral vectors of the present invention can be used to deliver any foreign nucleic acid with biological effects to treat or improve symptoms associated with any disorder associated with gene expression. In addition, the present invention can be used to treat any disease state for which delivery of therapeutic polypeptides is beneficial.

[0229] Illustrative disease states include, but are not limited to, cystic fibrosis (cystic fibrosis transmembrane regulator) and other lung diseases, hemophilia A (factor VIII), hemophilia B (factor IX), thalassemia (β-globin), anemia (erythropoietin) and other blood disorders, Alzheimer's disease (GDF; neprilysin), multiple sclerosis (β-interferon), Parkinson's disease (glial cell line-derived neurotrophic factor [GDNF]), Huntington's disease (inhibitory RNA, including but not limited to RNAi (such as siRNA or shRNA), antisense RNA or microRNA to remove repeats), amyotrophic lateral sclerosis, epilepsy (galanin, neurotrophins) and other neurological disorders, cancer (endostatin, angiostatin, TRAIL, FAS-ligand, cytokines including interferons);Inhibitory RNA, including but not limited to RNAi (such as siRNA or shRNA), antisense RNA and microRNA, including inhibitory RNA against VEGF, multidrug resistance gene products or cancer immunogens), diabetes (insulin, PGC-α1, GLP-1, myostatin propeptide, glucose transporter 4), muscular dystrophy (including Duchenne and Becker) (e.g., dystrophin, mini-dystrophin, micro-dystrophin, insulin-like growth factor I, sarcoglycans [e.g., α, β, γ], against myostatin or myostatin Inhibitory RNA [e.g., RNAi, antisense RNA or microRNA] directed against a propeptide of a protein, laminin-α2, fukutin-related protein, dominant negative myostatin, follistatin, activin type II soluble receptor, anti-inflammatory polypeptides (such as dominant mutants of IκB, myosin, dystrophin-related protein, small dystrophin-related protein), inhibitory RNA [e.g., RNAi, antisense RNA or microRNA] directed against a splice junction in the dystrophin gene to induce exon skipping [see, e.g., WO / 2003 / 095647], against U7 snRNA to induce exon skipping inhibitory RNA (e.g., RNAi, antisense RNA or microRNA) [see, e.g., WO / 2006 / 021724] and antibodies or antibody fragments to myostatin or myostatin propeptide), Gaucher disease (glucocerebrosidase), Hurler's disease (α-L-iduronidase), adenosine deaminase deficiency (adenosine deaminase), glycogen storage diseases (e.g., Fabry disease [α-galactosidase] and Pompedisease [lysosomal acid α-glucosidase]) and other metabolic defects (including other lysosomal storage diseases and glycogen storage diseases), congenital emphysema (α1-antitrypsin), Lesch-Nyhan Syndrome (hypoxanthine guanine phosphoribosyltransferase), Niemann-Pick disease (Niemann-Pick disease), disease)(sphingomyelinase), maple syrup urine disease(branched-chain ketoacid dehydrogenase), retinal degeneration (and other eye and retinal diseases;For example, PDGF, endostatin and / or angiostatin for macular degeneration), solid organ diseases such as brain diseases (including Parkinson's disease [GDNF], astrocytoma [endostatin, angiostatin and / or RNAi to VEGF], glioblastoma [endostatin, angiostatin and / or RNAi to VEGF]), liver diseases (RNAi (such as siRNA or shRNA), microRNA or antisense RNA for hepatitis B and / or hepatitis C genes), kidney diseases, heart diseases including congestive heart failure or peripheral arterial disease (PAD) (e.g., by delivering protein phosphatase inhibitor I [I-1], phospholamban, sarcoplasmic endoreticulum Ca; 2+-ATPase [serca2a], zinc finger proteins regulating phospholamban genes, Pim-1, PGC-1α, SOD-1, SOD-2, ECF-SOD, kallikrein, thymosin-β4, hypoxia-inducible transcription factor [HIF], βarkct, β2-adrenergic receptor, β2-adrenergic receptor kinase [βARK], phosphoinositide-3 kinase [PI3 kinase], calsarcin, angiogenic factors, S100A1, parvalbumin, adenylyl cyclase type 6, molecules that achieve knockdown of G protein-coupled receptor kinase type 2 (such as truncated constitutively active bARKct), inhibitory RNA against phospholamban [e.g., RNAi, antisense RNA or microRNA]; phospholamban inhibitory or dominant negative molecules such as phospholamban S16E, etc.)), arthritis (insulin-like growth factor), Joint disorders (insulin-like growth factor), intimal hyperplasia (e.g., by delivering enos, inos), improving survival of cardiac transplants (superoxide dismutase), IDS (soluble CD4), muscle wasting (insulin-like growth factor I, myostatin propeptide, anti-apoptotic factors, follistatin), limb ischemia (VEGF, FGF, PGC-1α, EC-SOD, HIF), kidney deficiency (erythropoietin), anemia (erythropoietin), arthritis (anti-inflammatory factors, such as IRAP and TNFα soluble receptors), hepatitis (α-interferon), LDL receptor deficiency (LDL receptor), hyperammonemia (ornithine transcarbamylase), spinocerebral ataxia (including SCA1, SCA2 and SCA3), phenylketonuria (phenylalanine hydroxylase), autoimmune diseases, etc. The present invention can further be used to increase the success rate of transplantation and / or reduce the negative side effects of organ transplantation or adjuvant therapy after organ transplantation (e.g., by blocking the production of cytokines by administering immunosuppressants or inhibitory nucleic acids). As another example, bone morphogenetic proteins (including RANKL and / or VEGF) can be administered with bone allografts, for example, after a break or surgical removal in a cancer patient.

[0230] Exemplary lysosomal storage diseases that may be treated according to the present invention include, but are not limited to, Hurler's Syndrome (MPS IH), Scheie's Syndrome (MPS IS), and Hurler-Scheie Syndrome (MPS IH / S) (α-L-iduronidase); Hunter's Syndrome (MPS II) (iduronate sulfate sulfatase); Sanfilippo A syndrome (MPS IIIA) (heparan-S-sulfate sulfaminidase), Sanfilippo B syndrome (MPS IIIB) (N-acetyl-D-glucosaminidase), Sanfilippo C syndrome (MPS IIIC) (acetyl-CoA-aminoglucosidase N-acetyltransferase), Sanfilippo D syndrome (MPS IIIC) (acetyl-CoA-aminoglucosidase N-acetyltransferase). MPS IIID) (N-acetyl-glucosaminine-6-sulfate sulfatase); Morquio A disease (MPS IVA) (galactosamine-6-sulfate sulfatase), Morquio B disease (MPS IV B) (β-galactosidase); Maroteaux-Imay disease (MPS VI) (arylsulfatase B); Sly syndrome (MPS VII) (β-glucuronidase); hyaluronidase deficiency (MPS IX) (hyaluronidase); sialidosis (mucolipidosis I), mucolipidosis II (I-cell disease) (N-acetylglucosaminyl-1-phosphotransferase catalytic subunit), mucolipidosis III (pseudo-Hurler polydystrophy) polydystrophy)(N-acetylglucosaminyl-1-phosphotransferase; type IIIA [catalytic subunit] and type IIIC [substrate recognition subunit]); GM1 gangliosidosis (ganglioside β-galactosidase), GM2 gangliosidosis type I (Tay-Sachs disease) (β-hexosaminidase A), GM2 gangliosidosis type II (Sandhoff's disease) (β-hexosaminidase B); Niemann-Pick disease (types A and B) (sphingomyelinase); Gaucher disease (glucocerebrosidase); Farber's disease (ceramidase); Fabry disease (α-galactosidase A);Krabbe's disease (galactosylceramide β-galactosidase); metachromatic leukodystrophy (arylsulfatase A); lysosomal acid lipase deficiencies, including Wolman's disease (lysosomal acid lipase); Batten disease (juvenile neuronal ceroid lipofuscinosis) (lysosomal transmembrane CLN3 protein); sialidosis (neuraminidase 1); galactosialidosis (Goldberg's syndrome) (protective protein / cathepsin A); alpha-mannosidosis (alpha-D-mannosidase); beta-mannosidosis (beta-D-mannosidosis); fucosidosis (alpha-D-fucosidase); aspartylglucosaminuria (N-aspartylglucosaminidase); and sialiduria (Na-phosphate co-transporter). ;

[0231] Exemplary glycogen storage diseases that may be treated according to the present invention include, but are not limited to, GSD type Ia (von Gierke disease) (glucose-6-phosphatase), GSD type Ib (glucose-6-phosphate translocase), GSD type Ic (microsomal phosphate or pyrophosphate transporter), GSD type Id (microsomal glucose transporter), GSD type II (including Pompe disease or infantile GSD type IIa (lysosomal acid α-glucosidase) and type IIb (Danon) (lysosomal membrane protein-2)), GSD types IIIa and IIIb (debranching enzymes; amyloglucosidase and oligoglucan transferase), GSD type IV (Andersen's disease), disease) (branching enzyme), GSD type V (McArdledisease) (muscle phosphorylase), GSD type VI (Hers' disease) (liver phosphorylase), GSD type VII (Tarui's disease) (phosphofructokinase), GSD type VIII / IXa (X-linked phosphorylase kinase), GSD type IXb (liver and muscle phosphorylase kinase), GSD type IXc (liver phosphorylase kinase), GSD type IXd (muscle phosphorylase kinase), GSD O (glycogen synthase), Fanconi-Bickel syndrome (glucose transporter 2), phosphoglucose isomerase deficiency, muscle phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, fructose 1,6-bisphosphatase deficiency, phosphoenolpyruvate carboxykinase deficiency, and lactate dehydrogenase deficiency.

[0232] Nucleic acids and polypeptides that can be delivered to the myocardium include nucleic acids and polypeptides that are beneficial for treating damaged, degenerated or atrophic myocardium and / or congenital heart defects. For example, angiogenic factors that can be used to promote vascularization in the treatment of heart disease include, but are not limited to, vascular endothelial growth factor (VEGF), VEGF II, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF121, VEGF138, VEGF145, VEGF165, VEGF189, VEGF206, hypoxia-inducible factor 1α (HIF 1α), endothelial NO synthase (eNOS), iNOS, VEFGR-1 (Flt1), VEGFR-2 (KDR / Flk1), VEGFR-3 (Flt4), angiogenin, epidermal growth factor (EGF), angiogenin, platelet-derived growth factor, angiogenic factor, transforming growth factor α (TGF-α), transforming growth factor β (TGF-β), vascular permeability factor (VPF), tumor necrosis factor α (TNF-α), interleukin 3 (IL-3), interleukin 8 (IL-8), platelet-derived endothelial growth factor (PD-EGF), granulocyte colony-stimulating factor (G-CSF), hepatocyte growth factor (HGF), scatter factor (SF), pleitrophin, proliferative factor, follistatin, placental growth factor (PIGF), midkine, platelet-derived growth factor-BB (PDGF), frac chemokine (frac talkine), ICAM-1, angiopoietin-1 and -2 (Ang1 and Ang2), Tie-2, neuropilin-1, ICAM-1, chemokines and cytokines that stimulate the migration of smooth muscle cells, monocytes or leukocytes, anti-apoptotic peptides and proteins, fibroblast growth factor (FGF), FGF-1, FGF-1b, FGF-1c, FGF-2, FGF-2b, FGF-2c, FGF-3, FGF-3b, FGF-3c, FGF-4, FGF-5, FGF-7, FGF-9, acidic FGF, basic FGF, monocyte chemoattractant protein-1, granulocyte macrophage colony stimulating factor, insulin-like growth factor-1 (IGF-1), IGF-2, early growth response factor-1 (EGR-1), ETS-1, human tissue kallikrein (HK), matrix metalloproteinases, chymase, urokinase-type plasminogen activator and heparinase. (See, e.g., U.S. Patent Application No. 20060287259 and U.S. Patent Application No. 20070059288).

[0233] The most common congenital heart disease found in adults is the bicuspid aortic valve, and atrial septal defects are the cause of 30-40% of congenital heart diseases seen in adults. The most common congenital heart defect observed in the pediatric population is a ventricular septal defect. Other congenital heart diseases include Eisenmenger's syndrome, patent ductus arteriosus, pulmonary stenosis, coarctation of the aorta, transposition of the great arteries, tricuspid atresia, univentricular heart, Ebstein'sanomaly, and double outlet of the right ventricle. Many studies have identified the putative genetic loci associated with one or more of these congenital heart diseases. For example, the putative gene for congenital heart disease associated with Down syndrome is 21q22.2-q22.3 between ETS2 and MX1. Similarly, most cases of DiGeorge syndrome are caused by the deletion of chromosome 22q11.2 (DiGeorge syndrome chromosome region or DGCR). Several genes are lost in this deletion, including the putative transcription factor TUPLE1. This deletion is associated with a variety of phenotypes, such as Shprintzen syndrome; conotruncal facies (or Takao syndrome); and separate outflow tract defects of the heart, including Tetralogy of Fallot, truncus arteriosus, and interrupted aortic arch. All of the above conditions can be treated according to the present invention.

[0234] Other important diseases of the heart and vascular system are also believed to have a genetic, often polygenic, etiological component. These disorders include, for example, hypoplastic left heart syndrome, valvular heart dysplasia, Pfeiffer cardiocranial syndrome, oculofaciocardiodental syndrome, Kapur-Toriello syndrome, Sonoda syndrome, Ohdo Blepharophimosis syndrome, cardio-hand syndrome, Pierre-Robin syndrome, Hirschsprung disease, Kousseff syndrome, Grange occlusive arterial syndrome, Kearns-Sayre syndrome, Kartagener syndrome, Alagille syndrome, Ritscher-Schinzel syndrome, Ivemark syndrome, Young-Simpson syndrome, and schwann syndrome. syndrome, hemochromatosis, Holzgreve syndrome, Barth syndrome, Smith-Lemli-Opitz syndrome, glycogen storage disease, Gaucher-like disease, Fabry disease, Lowry-Maclean syndrome, Rett syndrome, Opitz syndrome, Marfan syndrome, Miller-Dieker lissencephalysyndrome, mucopolysaccharidoses, Bruada syndrome, humerospinaldysostosis, Phaver syndrome, McDonough syndrome, Marfanoid hypermobility syndrome, atransferrinemia, Cornelia de Lange syndromesyndrome, Leopard syndrome, Diamond-Blackfan anemia, Steinfeld syndrome, progeria and Williams-Beuren syndrome. All of these conditions can be treated according to the present invention.

[0235] Anti-apoptotic factors can be delivered to skeletal muscle, diaphragm muscle, and / or myocardium to treat muscle wasting diseases, limb ischemia, myocardial infarction, heart failure, coronary artery disease, and / or type I or type II diabetes.

[0236] Nucleic acids that can be delivered to skeletal muscle include nucleic acids that are beneficial for treating damaged, degenerated and / or atrophic skeletal muscle. Genetic defects that cause muscular dystrophy are known for many forms of the disease. These defective genes either fail to produce protein products, or produce protein products that do not function properly, or produce dysfunctional protein products that interfere with the normal function of the cell. Heterologous nucleic acids can encode therapeutic functional proteins or polynucleotides that inhibit the production or activity of dysfunctional proteins. Polypeptides that can be expressed from or inhibited by the delivered nucleic acid (e.g., by delivery of RNAi, microRNA, or antisense RNA) include, but are not limited to, dystrophin, mini-dystrophin, or micro-dystrophin (Duchene's MD and Becker MD); dystrophin-related glycoproteins β-sarcoglycan (limb-girdle type MD 2E), δ-sarcoglycan (limb-girdle type MD 2 2F), α-sarcoglycan (limb-girdle type MD 2D), and γ-sarcoglycan (limb-girdle type MD 2C), dystrophin-related proteins (utrophin), calpain (autosomal recessive limb-girdle type MD 2 2A type), caveolin-3 (autosomal dominant limb-girdle MD), laminin-α2 (congenital MD with zonal protein deficiency), miniagrin (congenital MD with laminin-α2 deficiency), fukutin (congenital MD with Fukuyama type), emerin (Emery-Dreifuss MD), sarcomeric protein, lamin A / C, calpain-3, dysferlin and / or telethonin. In addition, the heterologous nucleic acid can encode mir-1, mir-133, mir-206, mir-208 or antisense RNA, RNAi (e.g., siRNA or shRNA) or microRNA to induce exon skipping in the defective dystrophin gene.

[0237] In certain embodiments, the nucleic acid is delivered to the tongue muscle (e.g., to treat dystrophic tongue). The method of delivery to the tongue can be by any method known in the art, including direct injection, oral administration, topical administration to the tongue, intravenous administration, intraarticular administration, etc.

[0238] The aforementioned proteins may also be administered to the diaphragm muscle to treat muscular dystrophy.

[0239] Alternatively, a gene transfer vector encoding any other therapeutic polypeptide may be administered.

[0240] In certain embodiments, viral vectors according to the invention are used to deliver nucleic acids of interest as described herein to skeletal muscle, diaphragm muscle and / or myocardium, e.g., to treat conditions associated with one or more of these tissues, such as muscular dystrophy, heart disease (including PAD and congestive heart failure), and the like.

[0241] Gene transfer has great potential use in understanding disease states and providing therapy for disease states. There are many genetic diseases in which defective genes are known and have been cloned. Generally, the above disease states are divided into two categories: deficiency states that are usually inherited in a recessive manner, usually enzyme deficiency states; and imbalance states, which may involve regulatory or structural proteins and are usually inherited in a dominant manner. For deficiency state diseases, gene transfer can be used to make normal genes enter the affected tissues for replacement therapy, and use inhibitory RNA (such as RNAi (e.g., siRNA or shRNA), microRNA or antisense RNA) to establish animal models of the disease. For unbalanced disease states, gene transfer can be used to establish disease states in model systems, which can then be used to fight against the disease state. Therefore, the viral vector according to the present invention allows the treatment of genetic diseases. As used herein, the disease state is treated by partially or completely remedying the deficiency or imbalance that causes the disease or makes it more serious. The application of site-specific recombination of nucleic acid sequences that cause mutations or correct defects is also possible.

[0242] In some embodiments, the condition treatable by the methods of the present invention can be a hereditary cardiomyopathy (e.g., hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), restrictive cardiomyopathy (RCM), left ventricular noncompaction cardiomyopathy (LVNC), etc.), heart failure, hypertension, ischemic heart disease, myocardial infarction, arrhythmia, cor pulmonale, congenital heart disease, donor hearts for transplantation, carditis, rheumatic heart disease, trauma-related heart damage, aging-related heart disease, or any combination thereof.

[0243] In certain embodiments, the nucleic acid is delivered to the liver. The method of delivery to the liver can be by any method known in the art, including injection into the liver, injection into the portal vein, or any combination thereof.

[0244] As another aspect, the viral vector of the present invention can be used to generate an immune response in a subject. According to this embodiment, a viral vector comprising a nucleic acid encoding an immunogen can be administered to a subject, and an active immune response (optionally, a protective immune response) to the immunogen is generated by the subject. The immunogen is as described above.

[0245] Alternatively, a viral vector can be administered to an ex vivo cell and the altered cell administered to a subject. A heterologous nucleic acid is introduced into a cell and the cell is administered to a subject, wherein the heterologous nucleic acid encoding an immunogen is optionally expressed and an immune response to the immunogen is induced in the subject. In a specific embodiment, the cell is an antigen presenting cell (e.g., a dendritic cell).

[0246] An "active immune response" or "active immunity" is characterized by "the involvement of host tissues and cells following encounter with an immunogen. It involves differentiation and proliferation of immunocompetent cells in the lymphoreticular tissue, which results in the synthesis of antibodies or the development of cell-mediated reactivity, or both." Herbert B. Herscowitz, Immunophysiology: Cell Function and Cellular Interactions in Antibody Formation, IMMUNOLOGY: BASIC PROCESSES 117 (Joseph A. Bellanti, ed., 1985). In other words, after exposure to an immunogen through infection or vaccination, the host mounts an active immune response. Active immunity can be contrasted with passive immunity, which is achieved by "transfer of preformed substances (antibodies, transfer factors, thymic grafts, interleukin-2) from an actively immune host to a non-immune host." Ibid.

[0247] An "active immune response" or "active immunity" is characterized by "the involvement of host tissues and cells following encounter with an immunogen. It involves differentiation and proliferation of immunocompetent cells in the lymphoreticular tissue, which results in the synthesis of antibodies or the development of cell-mediated reactivity, or both." Herbert B. Herscowitz, Immunophysiology: Cell Function and Cellular Interactions in Antibody Formation, IMMUNOLOGY: BASIC PROCESSES 117 (Joseph A. Bellanti, ed., 1985). In other words, after exposure to an immunogen through infection or vaccination, the host mounts an active immune response. Active immunity can be contrasted with passive immunity, which is achieved by "transfer of preformed substances (antibodies, transfer factors, thymic grafts, interleukin-2) from an actively immune host to a non-immune host." Ibid.

[0248] The viral vectors of the invention can also be administered for cancer immunotherapy, i.e., by administering a viral vector expressing a cancer cell antigen (or an immunologically similar molecule) or any other immunogen that generates an immune response against a cancer cell. For illustration, an immune response can be generated in a subject against a cancer cell antigen, e.g., to treat a cancer patient, by administering a viral vector comprising a heterologous nucleotide sequence encoding a cancer cell antigen. The viral vector can be administered to a subject in vivo or by using an ex vivo method as described herein.

[0249] As used herein, the term "cancer" encompasses cancers that form tumors. Likewise, the term "cancerous tissue" encompasses tumors. "Cancer cell antigens" encompass tumor antigens.

[0250] The term "cancer" has its understood meaning in the art, e.g., an uncontrolled growth of tissue with the potential to spread to distal parts of the body (i.e., metastasis). Exemplary cancers include, but are not limited to, leukemia, lymphoma (e.g., Hodgkin and non-Hodgkin lymphomas), colorectal cancer, kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, testicular cancer, ovarian cancer, uterine cancer, cervical cancer, brain cancer (e.g., glioma and glioblastoma), bone cancer, sarcoma, melanoma, head and neck cancer, esophageal cancer, thyroid cancer, etc. In an embodiment of the present invention, the present invention is implemented to treat and / or prevent cancers that form tumors.

[0251] The term "tumor" is also understood in the art to be an abnormal mass of undifferentiated cells, such as in a multicellular organism. Tumors can be malignant or benign. In representative embodiments, the methods disclosed herein are used to prevent and treat malignant tumors.

[0252] Cancer cell antigens have been described above. The term "treating cancer" or "treatment of cancer" is intended to reduce the severity of cancer or prevent or at least partially eliminate cancer. For example, in a specific context, these terms indicate the prevention or reduction or at least partially eliminate the metastasis of cancer. In other representative embodiments, these terms indicate that the growth of metastatic nodules (e.g., after surgical removal of the primary tumor) is prevented or reduced or at least partially eliminated. The term "prevention of cancer" or "preventing cancer" is intended to mean that these methods at least partially eliminate or reduce the incidence or onset of cancer. In other words, the onset or progression of cancer in a subject can be slowed down, controlled, reduced in likelihood or probability, or delayed.

[0253] In a specific embodiment, cells can be removed from a subject with cancer and contacted with a viral vector according to the invention. The modified cells are then administered to the subject, thereby inducing an immune response against the cancer cell antigen. This method is particularly advantageous for immunocompromised subjects who are unable to generate a sufficient immune response in vivo (i.e., unable to generate a sufficient amount of enhanced antibodies).

[0254] It is known in the art that immune responses can be enhanced by immunomodulatory cytokines (e.g., α-interferon, β-interferon, γ-interferon, ω-interferon, τ-interferon, interleukin-1α, interleukin-1β, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-18, B cell growth factor, CD40 ligand, tumor necrosis factor-α, tumor necrosis factor-β, monocyte chemoattractant protein-1, granulocyte-macrophage colony stimulating factor and lymphotoxin). Therefore, immunomodulatory cytokines (e.g., CTL inducible cytokines) can be administered to a subject together with a viral vector.

[0255] The cytokine may be administered by any method known in the art. Exogenous cytokines may be administered to the subject, or, alternatively, a nucleotide sequence encoding the cytokine may be delivered to the subject using a suitable vector and the cytokine produced in vivo.

[0256] Viral vectors can further be used to target neural cells for research purposes, such as for studying nervous system function in vitro or in animals or for producing and / or studying animal models of disease. In other embodiments, viral vectors can be used to specifically deliver toxic agents or enzymes that produce toxic agents (e.g., thymidine kinase) to neural cells to kill some or all cells.

[0257] In addition, the viral vector according to the present invention can be further used in diagnostic and screening methods, whereby the target gene is transiently or stably expressed in a cell culture system or alternatively in a transgenic animal model. The present invention can also be implemented to deliver nucleic acids for the purpose of protein production, for example, for laboratory, industrial or commercial purposes.

[0258] The recombinant virus vector according to the present invention can be used in both veterinary and medical applications. Suitable subjects include both birds and mammals. The term "bird" as used herein includes but is not limited to chickens, ducks, geese, quails, turkeys, pheasants, parrots, parakeets. The term "mammal" as used herein includes but is not limited to people, primates, non-human primates (e.g., monkeys and baboons), cattle, sheep, goats, pigs, horses, cats, dogs, rabbits, rodents (e.g., rats, mice, hamsters, etc.), etc. Human subjects include neonates, infants, teenagers and adults. Optionally, the subject "needs" the method of the present invention, for example, because the subject suffers from the following illness or is believed to be in its risk, the illness includes those described herein or will benefit from the delivery of nucleic acids including those described herein. For example, in a specific embodiment, the subject suffers from (has suffered from) demyelinating disease or spinal cord or brain injury, or is in the risk of demyelinating disease or spinal cord or brain injury. As another option, the subject can be an animal model of laboratory animals and / or diseases.

[0259] In some embodiments, the mammalian subject (e.g., human patient) may have previously received gene therapy treatment with AAV particles (e.g., non-AAV6 particles) of a serotype other than the serotype of the capsid backbone (e.g., not AAV6).

[0260] One aspect of the invention is a method for transferring nucleotide sequences to cells in vitro. The viral vector can be introduced into the cells at an appropriate multiplicity of infection according to standard transduction methods suitable for the particular target cell. The titer of the viral vector or capsid to be administered can vary depending on the type and number of target cells and the particular viral vector or capsid, and can be determined by one skilled in the art without undue experimentation. In a specific embodiment, at least about 103 infectious units, more preferably at least about 10 5 infectious units into cells.

[0261] The cells into which the viral vectors can be introduced can be of any type, including but not limited to neural cells (including cells of the peripheral and central nervous systems, in particular cells such as neurons, oligodendrocytes, glial cells, astrocytes), lung cells (e.g., bronchiolar epithelial cells, alveolar epithelial cells, lung ionocytes, ciliated epithelial cells and / or lung stem cells (e.g., basal cells and / or rod cells)), eye cells (including retinal cells, retinal pigment epithelial cells and corneal cells), epithelial cells (e.g., intestinal and respiratory epithelial cells), skeletal muscle cells (including myoblasts, myotubes and myofibers), diaphragm cells, dendritic cells, pancreatic cells (including pancreatic islet cells), hepatocytes, gastrointestinal cells (including smooth muscle cells, epithelial cells), heart cells (including cardiomyocytes), bone cells (e.g., bone marrow stem cells), hematopoietic stem cells, spleen cells, keratinocytes, fibroblasts, endothelial cells, prostate cells, joint cells (including, for example, cartilage, meniscus, synovium and bone marrow), germ cells, etc. Alternatively, the cell can be any progenitor cell. As yet another alternative, the cell can be a stem cell (e.g., a neural stem cell, a liver stem cell). As yet another alternative, the cell can be a cancer or tumor cell (cancer and tumor are described above). In addition, as indicated above, the cell can be from a species of any origin.

[0262] For the purpose of administering modified cells to a subject, a viral vector can be introduced into a cell in vitro. In a specific embodiment, cells have been removed from a subject, a viral vector is introduced therein, and then the cells are placed back into the subject. Cells are removed from a subject for ex vivo treatment and then introduced into a subject as known in the art (see, e.g., U.S. Patent No. 5,399,346). Alternatively, a recombinant viral vector is introduced into a cell from another subject, into a cultured cell, or into a cell from any other suitable source, and the cell is administered to a subject in need thereof.

[0263] Suitable cells for ex vivo gene therapy are described above. The dosage of cells to be administered to a subject will vary depending on the age, condition and species of the subject, the cell type, the nucleic acid expressed by the cell, the mode of administration, etc. Typically, at least about 10 μg of the cell will be administered per dose in a pharmaceutically acceptable carrier. 2 To about 10 8 or about 10 3 To about 10 6 In certain embodiments, cells transduced with a viral vector are administered to a subject in an effective amount in combination with a pharmaceutical carrier.

[0264] In some embodiments, cells transduced with viral vectors may be administered to induce an immunogenic response to the delivered polypeptide (e.g., expressed as a transgene or in a capsid). Typically, a certain amount of cells expressing an effective amount of a polypeptide in combination with a pharmaceutically acceptable carrier is administered. Optionally, the dose is sufficient to produce a protective immune response (as defined above). The degree of protection conferred need not be complete or permanent, as long as the benefits of administering the immunogenic polypeptide outweigh any disadvantages thereof.

[0265] Another aspect of the present invention is a method of administering a viral vector or capsid of the present invention to a subject. In a specific embodiment, the method includes a method of delivering a target nucleic acid to an animal subject, the method comprising: administering an effective amount of a viral vector according to the present invention to the animal subject. The viral vector of the present invention can be administered to a human subject or animal in need by any means known in the art. Optionally, the viral vector is delivered in an effective dose in a pharmaceutically acceptable carrier.

[0266] The viral vector of the present invention may be further administered to a subject to induce an immunogenic response (e.g., as a vaccine). Typically, the vaccine of the present invention comprises an effective amount of a combination of a virus and a pharmaceutically acceptable carrier. Optionally, the dose is sufficient to produce a protective immune response (as defined above). The degree of protection conferred does not need to be complete or permanent, as long as the benefits of administering the immunogenic polypeptide outweigh any of its disadvantages. The subject and the immunogen are as described above.

[0267] The dosage of the viral vector to be administered to a subject will depend on the mode of administration, the disease or condition to be treated, the condition of the individual subject, the particular viral vector and the nucleic acid to be delivered, and can be determined in a routine manner. An exemplary dosage for achieving a therapeutic effect is at least about 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 10 15 , 10 16 , 10 17 , 10 18 transduction unit or more preferably about 10 7 or 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 or 10 14 transduction unit, even more preferably about 1012 In some embodiments, the therapeutically effective amount of AAV particles is about 1×10 12 vg (particles) / kg to about 1×10 14 particles / kg, for example, about 1×10 12 , 2×10 12 , 3×10 12 , 4×10 12 , 5×10 12 , 6×10 12 ,7×10 12 , 8×10 12 ,9×10 12 , 1×10 13 , 2×10 13 , 3×10 13 , 4×10 13 , 5×10 13 or 6×10 13 or any value or range therein.

[0268] For example, in some embodiments, a therapeutically effective amount of an AAV particle of the invention may be about 1.5×10 12 Particles / kg to about 5.5×10 12 particles / kg, about 1×10 12 Particles / kg is about 5.3×10 13 particles / kg, about 1×10 13 Particles / kg to about 6×10 13 particles / kg, or about 1×10 12 particles / kg, about 5×10 12 particles / kg, about 1.2×10 13 particles / kg or about 3.5×10 13 Particles / kg.

[0269] Exemplary modes of administration include oral, rectal, transmucosal, topical, intranasal, inhalation (e.g., via aerosol), buccal (e.g., sublingual), vaginal, intrathecal, intraocular, transdermal, intrauterine (or intraovo), parenteral (e.g., intravenous, subcutaneous, intradermal, intramuscular [including administration to skeletal muscle, diaphragm and / or myocardium], intradermal, intrapleural, intracerebral and intraarticular), topical (e.g., to both the skin and mucosal surfaces, including airway surfaces, and transdermal administration), intralymphatic, etc., and direct tissue or organ injection (e.g., to the liver, skeletal muscle, myocardium, diaphragm or brain). Administration can also be to a tumor (e.g., in or near a tumor or lymph node). In any given case, the most appropriate route will depend on the nature and severity of the condition being treated and the nature of the specific carrier used.

[0270] In some embodiments, the viral vector is directly applied to the CNS, such as the brain or spinal cord. Direct application can result in high specificity of CNS cell transduction, for example, wherein at least 80%, 85%, 90%, 95% or more of the transduced cells are CNS cells. Any method known in the art for directly applying the vector to the CNS can be used. The vector can be introduced into the spinal cord, brainstem (medulla oblongata, pons), midbrain (hypothalamus, thalamus, epithalamus, pituitary, substantia nigra, pineal gland), cerebellum, telencephalon (striatum, cerebrum, including occipital lobe, temporal lobe, parietal lobe and frontal lobe, cortex, basal ganglia, hippocampus and amygdala), limbic system, neocortex, striatum, cerebrum and hypothalamus. The vector can also be applied to different areas of the eye (such as the retina, cornea or optic nerve). The vector can be delivered to the cerebrospinal fluid (for example, by lumbar puncture) to apply the vector more dispersedly.

[0271] The delivery vector can be administered to the desired region of the CNS by any route known in the art, including, but not limited to, intrathecal, intracerebral, intraventricular, intranasal, intraauricular, intraocular (e.g., intravitreal, subretinal, anterior chamber), and periocular (e.g., sub-Tenon's region) delivery, or any combination thereof.

[0272] Administration to skeletal muscle according to the present invention includes, but is not limited to, administration to skeletal muscle in the limbs (e.g., upper arm, lower arm, thigh and / or calf), back, neck, head (e.g., tongue), chest, abdomen, pelvis / perineum and / or fingers / toes. Suitable skeletal muscle tissue includes, but is not limited to, abductor digiti minimi (in the hand), abductor digiti minimi (in the foot), abductor hallucis (digital) muscle, abductor ossis metatarsi quinti, abductor pollicis brevis, abductor pollicis longus, adductor brevis, adductor pollicis longus, adductor pollicis magnus, adductor pollicis anterior, anconeus, scalene anterior (anterior) muscles. scalene), knee joint muscle, biceps brachii, biceps femoris, brachialis, brachioradialis, buccinator, coracobrachialis, corrugator supercilii, deltoid, depressor anguli oris, depressor labii inferioris, digastric, dorsal interosseous muscles (in the hand), dorsal interosseous muscles (in the foot), extensor carpi radialis brevis, extensor carpi radialis longus, extensor digiti minimi, extensor digiti brevis, extensor digiti longus, extensor hallucis brevis, extensor hallucis longus, extensor index finger, extensor hallucis brevis, extensor hallucis longus, flexor carpi radialis, flexor carpi ulnaris, flexor digiti minimi brevis (in the hand), flexor digiti minimi brevis (in the foot), flexor digiti brevis, flexor digiti longus, flexor digiti profundus, flexor digiti superficialis, flexor hallucis brevis, flexor hallucis longus, flexor hallucis brevis pollicis brevis), flexor pollicis longus (flexorpollicislongus), frontalis, gastrocnemius, geniohyoid, gluteus maximus, gluteus medius, gluteus minimus, gracilis, iliocostalis cervi, iliocostalis lumborum, iliocostalis thoracis, iliacus, gemellia inferior, inferior oblique, inferior rectus, infraspinatus, interspinalis, intertransverse processes, lateral pterygoid, lateral rectus, latissimus dorsi, levator anguli oris, levator labii superioris, levator labii alar nasalis superioris, levator palpebrae superioris, levator scapulae, long rotator, longissimus capitis, longissimus cervi, longissimus thoracis, longissimus capitis, longissimus cervi , lumbricals (in the hand), lumbricals (in the foot), masseter, medial pterygoid, medial rectus, scalene medius, multifidus, mylohyoid, oblique capitis inferior, oblique capitis capitis superior, obturator externus, obturator internus, occipitalis, omohyoid, opponents of the thumb (toe), orbicularis oculi, orbicularis oris, palmaris interosseus, palmaris brevis, palmaris longus, pectineus, pectoralis major, pectoralis minor, peroneus brevis, peroneus longus, peroneus tertius, piriformis , plantaris interosseus, plantaris, platysma, popliteus, scalene posterior, pronator quadratus, pronator teres, psoas major, quadratus femoris, quadratus plantaris, rectus capitis anterior, rectus capitis lateralis, rectus capitis posterior major, rectus capitis posterior minor, rectus femoris, rhomboid major, rhomboid minor, risorius, sartorius, scalene minor, semimembranosus, semispinalis capitis, semispinalis cervicis, semispinalis thoracis, semitendinosus, serratus anterior, rotator brevis, soleus, spinalis capitis, spinalis cervicis, spinalis thoracis, splint capitis muscle, splenius, sternocleidomastoid, sternohyoid, sternothyroid, stylohyoid, subclavius, subscapularis, superior gemelli, superior oblique, superior rectus, supinator, supraspinatus, temporalis, tensor fasciae latae, teres major, teres minor, pectoralis, thyrohyoid, tibialis anterior, tibialis posterior, trapezius, triceps brachii, vastus intermedius, vastus lateralis, vastus medialis, zygomaticus major and zygomaticus minor, and any other suitable skeletal muscle known in the art.

[0273] AAV particles can be delivered to skeletal muscle by any suitable method, including, but not limited to, intravenous administration, intraarterial administration, intraperitoneal administration, isolated limb perfusion (optionally, isolated limb perfusion of the leg and / or arm; see, e.g., Arruda et al., (2005) Blood 105:3458-3464), and / or direct intramuscular injection.

[0274] Administration to the myocardium includes, but is not limited to, administration to the left atrium, right atrium, left ventricle, right ventricle, and / or septum. The viral vector may be delivered to the myocardium by any method known in the art, including, for example, intravenous administration, intra-arterial administration (such as intra-aortic administration), direct cardiac injection (e.g., to the left atrium, right atrium, left ventricle, right ventricle), and / or coronary artery perfusion.

[0275] Administration to the diaphragm can be by any suitable method, including intravenous administration, intraarterial administration, and / or intraperitoneal administration.

[0276] Delivery to any of these tissues can also be achieved by delivering a reservoir comprising the viral vector, which can be implanted in skeletal muscle, cardiac muscle, and / or diaphragm tissue, or the tissue can be contacted with a membrane or other matrix comprising the viral vector. Examples of such implantable matrices or substrates are described in U.S. Patent No. 7,201,898.

[0277] In specific embodiments, viral vectors according to the invention are administered to skeletal muscle, diaphragm muscle, and / or cardiac muscle (eg, to treat muscular dystrophy or heart disease [eg, PAD or congestive heart failure]).

[0278] The present invention can be used to treat disorders of skeletal muscle, cardiac muscle and / or diaphragm. Alternatively, the present invention can be practiced to deliver nucleic acids to skeletal muscle, cardiac muscle and / or diaphragm, which are used as a platform for producing protein products (e.g., enzymes) or non-translated RNA (e.g., RNAi, microRNA, antisense RNA) that circulate normally in the blood, or for systemic delivery to other tissues to treat disorders (e.g., metabolic disorders, such as diabetes (e.g., insulin), hemophilia (e.g., factor IX or factor VIII), or lysosomal storage diseases (such as Gaucher disease [glucocerebrosidase], Pompe disease [lysosomal acid α-glucosidase] or Fabry disease [α-galactosidase A]) or glycogen storage diseases (such as Pompe disease [lysosomal acid α-glucosidase]). Other suitable proteins for treating metabolic disorders are as described above.

[0279] In some embodiments, more than one administration (eg, two, three, four, or more administrations) may be used to achieve desired gene expression levels at various intervals (eg, daily, weekly, monthly, yearly, etc.).

[0280] Pharmaceutical compositions suitable for oral administration may be presented as discrete units, such as capsules, cachets, lozenges or tablets, each containing a predetermined amount of the composition of the invention; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; or oil-in-water or water-in-oil emulsions. Oral delivery may be performed by compounding the viral vector of the invention with a carrier that is capable of withstanding degradation by digestive enzymes in the intestinal tract of an animal. Examples of such carriers include plastic capsules or tablets as known in the art. Such formulations are prepared by any suitable pharmaceutical method, which includes the step of associating the composition with a suitable carrier (which may contain one or more auxiliary ingredients as described above). Typically, pharmaceutical compositions according to embodiments of the present invention are prepared by uniformly and intimately mixing the composition with a liquid or finely divided solid carrier or both, and then molding the resulting mixture as desired. For example, tablets may be prepared by compressing or molding a powder or granules containing the composition, optionally with one or more auxiliary ingredients. Compressed tablets are prepared by compressing a composition (such as a powder or granules) in a free-flowing form in a suitable machine, optionally mixed with one or more binders, lubricants, inert diluents and / or surfactants / dispersants. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

[0281] Pharmaceutical compositions suitable for buccal (sublingual) administration include lozenges comprising the composition of this invention in a flavored base, usually sucrose and acacia or tragacanth; and pastilles comprising the composition in an inert base such as gelatin and glycerin or sucrose and acacia.

[0282] Pharmaceutical compositions suitable for parenteral administration may include sterile aqueous and non-aqueous injection solutions of the compositions of the present invention, the preparations being optionally isotonic with the blood of the intended recipient. These preparations may contain antioxidants, buffers, antibacterial agents, and solutes, which make the compositions isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions, solutions, and emulsions may include suspending agents and thickening agents. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils (such as olive oil), and injectable organic esters (such as ethyl oleate). Aqueous carriers include water, alcohol / water solutions, emulsions, or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include liquid and nutrient supplements, electrolyte supplements (such as those based on Ringer's dextrose), etc. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases, among others.

[0283] The compositions may be presented in unit / dose or multi-dose sealed containers (e.g., sealed ampoules and vials) and may be stored in a freeze-dried (lyophilized) state requiring only the addition of a sterile liquid carrier, such as saline or water for injection, immediately prior to use.

[0284] Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules and tablets of the types previously described. For example, an injectable, stable, sterile composition of the present invention in a unit dosage form in a sealed container can be provided. The composition can be provided in the form of a lyophilized product, which can be reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection into a subject. The unit dosage form can be about 1 μg to about 10g of the composition of the present invention. When the composition is substantially insoluble in water, a sufficient amount of a physiologically acceptable emulsifier may be included in an amount sufficient to emulsify the composition in an aqueous vehicle. One such useful emulsifier is phosphatidylcholine.

[0285] Pharmaceutical compositions suitable for rectal administration may be presented as unit-dose suppositories. These may be prepared by mixing the composition with one or more conventional solid carriers, such as, for example, cocoa butter, and then shaping the resulting mixture.

[0286] The pharmaceutical composition of the present invention suitable for topical application to the skin can be in the form of an ointment, cream, lotion, paste, gel, spray, aerosol or oil. Available carriers include, but are not limited to, vaseline, lanolin, polyethylene glycol, alcohol, transdermal enhancers and combinations of two or more thereof. In some embodiments, for example, topical delivery can be performed by mixing the pharmaceutical composition of the present invention with a lipophilic agent (e.g., DMSO) that can enter the skin.

[0287] Pharmaceutical compositions suitable for transdermal administration may be in the form of discrete patches, which are suitable for maintaining close contact with the epidermis of a subject for a long period of time. Compositions suitable for transdermal administration may also be delivered by iontophoresis (see, e.g., Pharm. Res. 3: 318 (1986)), and are generally in the form of optional buffered aqueous solutions of the compositions of the present invention. Suitable formulations may include citrate or bis\tris buffer (pH 6) or ethanol / water, and may contain 0.1 to 0.2 M of active ingredient.

[0288] The viral vector disclosed herein can be applied to the lungs of a subject by any suitable means, for example, by administering an aerosol suspension of inhalable particles containing the viral vector inhaled by the subject. The inhalable particles can be liquid or solid. An aerosol containing liquid particles of the viral vector can be produced by any suitable means (such as using a pressure-driven aerosol nebulizer or ultrasonic nebulizer as known to those skilled in the art). See, for example, U.S. Patent No. 4,501,729. An aerosol containing solid particles of the viral vector can also be produced by any solid particulate medicament aerosol generator by techniques known in the pharmaceutical field.

[0289] The present invention will now be described with reference to the following examples. It should be understood that these examples are not intended to limit the scope of the claims to the present invention, but are intended to be examples of certain embodiments. Any changes in the illustrative methods that occur to those skilled in the art are intended to fall within the scope of the present invention.

[0290] Example

[0291] Example 1: Construction of modified AAVH43, AAVH48 and AAVH67 vectors.

[0292] The chimeric AAV capsid proteins AAVH43, AAVH48 and AAVH67 of the present invention are exemplary chimeric combinations of current serotypes primarily derived from AAV1-9 ( Figure 1 Compared to AAV6, AAVH43 has amino acid substitutions at least at the following positions: D24A, F129L, T194A, A196S, A197S, P200S, T201G, M203V, S205A, A224S, and T233Q, as well as L584F and V598A in VP3 VR-VIII, and T714S in VP3 VR-IX, as well as R311K, N313R, L640I, Q646L, and T722S elsewhere in VP3 ( Figure 1 and Figure 2 Compared to AAV6, AAVH48 shows different amino acid substitutions such as at least the following positions: V125I, F129L, G135A, E147D, I159V, T162S, Q164K, K168R, T194A, A196T, A197S, V198L, P200S and / or T201N, and L584F and V598A L583F and V598A of VP3 VR-VII ( Figure 1 and Figure 2Compared to AAV6, AAVH67 shows different amino acid substitutions at least at the following locations: D41N, F129L, K168R, T201N, and L235M, as well as A263E, S264T, T265A, A267S, and S268T in VP3 VR-I, and H272T and H642N elsewhere in VP3 ( Figure 1 and Figure 2 ). Amino acid substitutions compared to AAV9 are also shown in Figure 1 middle.

[0293] Example 2: AAVH43, AAVH48, and AAVH67 have different tissue tropism from AAV6.

[0294] Chimeric AAVH43, AAVH48, and AAVH67 viruses were injected into C57B6 mice (3 × 10 11 / mouse, n = 3 / group). Three weeks later, liver and heart tissues were harvested and fixed by high concentration sucrose to maintain GFP activity. Figure 3 GFP expression in the liver and heart of C57B6 mediated by AAVH43, AAVH48, and AAVH67 vectors with a CMV promoter is shown. Chimeric AAV vectors AAVH43, AAVH48, and AAVH67 showed significantly increased liver tropism, which is different from AAV6. GFP expression mediated by AAVH43 and AAVH48 was similar to AAV9. Expression levels in the heart showed no significant differences between the various vectors.

[0295] Example 3: AAVH43, AAVH48 and AAVH67 show CNS affinity in vivo.

[0296] AAVH43, AAVH48 and AAVH67 vectors containing the reporter gene lacZ driven by the CMV promoter were delivered to C57BL / 6 mice via intrathecal (IT) injection, with AAV9 as a positive control (n=4 per group). Before vector injection, 200 μL of 25% mannitol solution was given by tail vein injection to reduce intracranial pressure. 20 minutes later, 10 μL of viral vector (1×10 11 vg) were slowly injected into the cerebrospinal fluid (CSF) at the intervertebral space between lumbar vertebrae L3 and L4. Two weeks later, tissue samples were harvested for lacZ staining and immunostaining.

[0297] LacZ gene mediated by AAVH43, AAVH48 and AAVH67 vectors was expressed efficiently in the spinal cord via intrathecal injection and similarly to AAV9. The entire spinal cord from the lumbar to the cervical region showed LacZ expression ( Figure 4 and Figure 5 ). The infected cells are mainly distributed in the posterior cord and gray matter ( Figure 6 and Figure 7 In addition, all four vectors were very efficient in infecting dorsal root ganglion neurons ( Figure 8 and Fig. 9 ).

[0298] Example 4: AAVH43, AAVH48 and AAVH67 target neuronal cells in vivo.

[0299] Immunostaining showed that AAVH43, AAVH48, and AAVH67 vectors with the CMV promoter primarily infected neurons but not glial cells, similar to AAV9 ( Figure 10-12 ). In addition, AAVH43 and AAVH48 share some common features and infect the cerebellar cortex much more efficiently than AAV9 ( Fig.13 ). Those neurons showed a unique morphology as Purkinje cells. AAVH43, AAVH48, and AAVH67 mediated LacZ expression in the brainstem but not in the cerebral cortex ( Fig.14 ), similar to AAV9.

[0300] Injection into the midcerebroventricular cavity of newborn pups (a total of 5 × 10 10 After 6 weeks, AAVH43, AAVH48, and AAVH67-mediated LacZ expression was measured in the brain, and target gene expression was still high in the whole brain ( Fig.15 ).

[0301] Example 5: AAVH67 successfully mediates neuroprotective factors in the CNS and prolongs ALS survival.

[0302] The AAVH67 chimeric vector was used to mediate overexpression of thymosin β4 (Tβ4), a neuroprotective factor, in the CNS in a mouse model of amyotrophic lateral sclerosis (ALS). The AAVH67-delivered therapy significantly prolonged survival by up to 12 days, from 133 to 145 days ( Fig.16 The average survival time also increased from 128.9±2.6 days to 141.7±1.9 days ( Fig.17 AAVH67-CMV-thymosin treatment also delayed the time to ALS progression from 26.5±1.9 days to 34.0±2.1 days ( Fig.17AAVH67-mediated thymosin therapy also delayed ALS disease onset from 101.5 days to 108.5 days ( Fig.18 ). This successful application in animal models demonstrates that these modified chimeric vectors represent useful delivery vehicles for delivering therapeutic genes to patients with CNS diseases, such as, for example, ALS patients who require gene therapy to rescue neuronal function.

[0303] The foregoing is illustrative of the present invention and should not be construed as limiting the present invention. The present invention is defined by the following claims, including equivalents of the claims.

[0304] Table 1.

[0305]

[0306]

[0307] Table 2.

[0308]

[0309] Table 3.

[0310]

[0311]

[0312] sequence

[0313] SEQ ID NO: 1. AAVH43 VP1, VP2 and VP3

[0314]

[0315] SEQ ID NO: 2. AAVh43 VP1 and VP2

[0316]

[0317] SEQ ID NO: 3. AAVH43 VP3

[0318]

[0319] SEQ ID NO:4. AAVH43 VP1 and VP2

[0320]

[0321] SEQ ID NO:5. AAVH43VP3

[0322]

[0323] SEQ ID NO: 6. AAVH48 VP1, VP2 and VP3

[0324]

[0325] SEQ ID NO: 7. AAVH48 VP1 and VP2

[0326]

[0327] SEQ ID NO:8. AAVH48 VP3

[0328]

[0329] SEQ ID NO: 9. AAVH48 VP1 and VP2

[0330]

[0331] SEQ ID NO:10.AAVH48VP3

[0332]

[0333] SEQ ID NO:11.AAVH67 VP1 VP2VP3

[0334]

[0335] SEQ ID NO: 12. AAVH67 VP1 VP2

[0336]

[0337] SEQ ID NO: 13. AAVH67 VP3

[0338]

[0339] SEQ ID NO: 14. AAVH67 VP1 VP2

[0340]

[0341] SEQ ID NO: 15. AAVH67 VP3

[0342]

[0343] SEQ ID NO: 16. AAV6 VP1, VP2 and VP3, accession number AAB95450.1

[0344]

[0345] SEQ ID NO:17.AAV6 VP1 / 2, accession number AAB95450.1

[0346]

[0347] SEQ ID NO: 18. AAV6 VP3, accession number AAB95450.1

[0348]

[0349] SEQ ID NO:19.AAV6 VP1 / 2, accession number AF028704.1

[0350]

[0351] SEQ ID NO:20. AAV6 VP3, accession number AF028704.1

[0352]

[0353] SEQ ID NO:21. AAV9 VP1, VP2, VP3, accession number AAS99264.1

[0354]

[0355] SEQ ID NO:22. AAV9 VP1 / 2, accession number AAS99264.1

[0356]

[0357] SEQ ID NO:23. AAV9 VP3, accession number AAS99264.1

[0358]

[0359] SEQ ID NO:24.AAV9 VP1 / 2, accession number AY530579.1

[0360]

[0361] SEQ ID NO:25. AAV9 VP3, accession number AY530579.1

[0362]

[0363] Alignment of SEQ ID NOs: 1, 6, 11 and 16.

[0364]

[0365]

Claims

1. A chimeric adeno-associated virus (AAV) capsid of a first serotype, comprising VP1 capsid protein, VP2 capsid protein and VP3 capsid protein of the first serotype, wherein: a) the VP1 and / or the VP2 capsid protein comprises one or more substitutions at amino acid positions 24, 41, 125, 129, 135, 147, 159, 162, 164, 168, 194, 196, 197, 198, 200, 201, 203, 205, 224, 233 and / or 235, and b) the VP3 capsid protein comprises one or more amino acid substitutions in the VP3 variable region (VR); wherein the numbering corresponds to SEQ ID NO: 16 (AAV6 VP1 / 2 / 3), and wherein the chimeric AAV capsid has enhanced neurotropism compared to the neurotropism of a corresponding wild-type AAV capsid of the first serotype.

2. The chimeric AAV capsid of claim 1, wherein the one or more amino acid substitutions in the VP3 VR are in VP3 VR-I, VR-II, VR-III, VR-IV, VR-V, VR-VI, VR-VII, VR-VIII, HI loop and / or VR-IX.

3. The chimeric AAV capsid of claim 1 or 2, wherein the one or more amino acids in the VP3 VR are substituted at amino acid positions 263, 264, 265, 267 and / or 268 in VR-I.

4. The chimeric AAV capsid of any one of claims 1-3, wherein the one or more amino acid substitutions in the VP3VR are at amino acid positions 584 and / or 598 in VR-VIII.

5. The chimeric AAV capsid of any one of claims 1-4, wherein the one or more amino acids in the VP3VR are substituted at amino acid position 714 in VR-IX.

6. The chimeric AAV capsid of any one of claims 1-5, further comprising one or more substitutions outside of the VR in the VP3 capsid protein.

7. The chimeric AAV capsid of claim 6, wherein the one or more amino acid substitutions outside of the VR in the VP3 capsid protein comprise amino acid substitutions at positions 272, 311, 313, 640, 642, 646 and / or 722.

8. The chimeric AAV capsid of any one of claims 1-7, wherein the enhanced neurotropism is enhanced by about 5.0 fold or more compared to the neurotropism of the corresponding wild-type AAV capsid.

9. The chimeric AAV capsid of any one of claims 1-8, covalently linked, bound or encapsidated with a compound selected from the group consisting of: a DNA molecule (e.g., Cas9-plasmid), an RNA molecule (e.g., CRISPR RNA), a polypeptide, a carbohydrate, a lipid, a small organic molecule, and any combination thereof (e.g., CRISPR RNP).

10. The chimeric AAV capsid of any one of claims 1-9, wherein the first AAV serotype is AAV1, AAV2, AAV3, AAV4, AAV6, AAV7, AAV8 and / or AAV9.

11. The chimeric AAV capsid of any one of claims 1-10, wherein the first AAV serotype is AAV6.

12. The chimeric AAV capsid of any one of claims 1-11, comprising: The first AAV serotype, which is AAV6, one or more substitutions in the VP1 and / or VP2 capsid proteins at the following amino acid positions: 24 (e.g., D24A), 129 (e.g., F129L), 194 (e.g., T194A), 196 (e.g., A196S), 197 (e.g., A197S), 200 (e.g., P200S), 201 (e.g., T201G), 203 (e.g., M203V), 205 (e.g., S205A), 224 (e.g., A224S) and / or 233 (e.g., T233Q), one or more substitutions in the VP3 variable region (VR) at amino acid positions 584 (e.g., L584F) and / or 598 (V598A) in VR-VIII and / or at position 714 (e.g., T714S) in VR-IX, and Further comprising one or more VP3 amino acid substitutions at the following positions: 311 (eg, R311K), 313 (eg, N313R), 640 (eg, L640I), 646 (Q646L) and / or 722 (T722S).

13. The chimeric AAV capsid according to claim 12, wherein the one or more amino acid substitutions in the VP1 and / or VP2 include D24A, F129L, T194A, A196S, A197S, P200S, T201G, M203V, S205A, A224S and / or T233Q, wherein the one or more amino acid substitutions in VP3 VR include VR-III L584F and / or V598A and / or VR-IX T714S, and Wherein further VP3 amino acid substitutions include R311K, N313R, L640I, Q646L and / or T722S.

14. The chimeric AAV capsid according to claim 13, wherein the one or more amino acid substitutions in the VP1 and / or VP2 include D24A, F129L, T194A, A196S, A197S, P200S, T201G, M203V, S205A, A224S and T233Q, wherein the one or more amino acid substitutions in VP3 VR include VR-III L584F and V598A and / or VR-IXT714S, and Further VP3 amino acid substitutions included R311K, N313R, L640I, Q646L and T722S.

15. The chimeric AAV capsid of any one of claims 12-14, comprising, consisting essentially of, or consisting of an amino acid sequence that is at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO: 1 (AAVH43).

16. The chimeric AAV capsid of any one of claims 1-11, comprising: The first AAV serotype, which is AAV6, one or more substitutions in the VP1 and / or VP2 capsid proteins at the following amino acid positions: 125 (e.g., V125I), 129 (e.g., F129L), 135 (e.g., G135A), 147 (e.g., E147D), 159 (e.g., I159V), 162 (e.g., T162S), 164 (e.g., Q164K), 168 (e.g., K168R), 194 (e.g., T194A), 196 (e.g., A196T), 197 (e.g., A197S), 198 (e.g., V198L), 200 (e.g., P200S) and / or 201 (e.g., T201N), and One or more amino acid substitutions in the VP3 variable region (VR) at the following amino acid positions in VR-VIII: 584 (eg, L584F) and / or 598 (eg, V598A).

17. The chimeric AAV capsid of claim 16, wherein the one or more amino acid substitutions in the VP1 and / or VP2 include V125I, F129L, G135A, E147D, I159V, T162S, Q164K, K168R, T194A, A196T, A197S, V198L, P200S and / or T201N, and wherein the one or more amino acid substitutions in the VP3 VR include VR-VIII L584F and / or V598A.

18. The chimeric AAV capsid of claim 17, wherein the one or more amino acid substitutions in the VP1 and / or VP2 include V125I, F129L, G135A, E147D, I159V, T162S, Q164K, K168R, T194A, A196T, A197S, V198L, P200S and T201N, and wherein the one or more amino acid substitutions in the VP3 VR include VR-VIII L584F and V598A.

19. The chimeric AAV capsid of any one of claims 16-18, comprising, consisting essentially of, or consisting of an amino acid sequence that is at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO:6 (AAVH48).

20. The chimeric AAV capsid of any one of claims 1-11, comprising: The first AAV serotype, which is AAV6, one or more substitutions in the VP1 and / or VP2 capsid proteins at the following amino acid positions: 41 (e.g., D41N), 129 (e.g., F129L), 168 (e.g., K168R), 201 (e.g., T201N) and / or 235 (e.g., L235M), The VP3 variable region (VR) has one or more amino acid substitutions in VR-I at amino acid positions 263 (e.g., A263E), 264 (e.g., S264T), 265 (e.g., T265A), 267 (e.g., A267S) and / or 268 (e.g., S268T), and Further comprising one or more VP3 amino acid substitutions at the following positions: 272 (eg, H272T) and / or 642 (H642N).

21. The chimeric AAV capsid of claim 20, wherein the one or more amino acid substitutions in the VP1 and / or VP2 include D41N, F129L, K168R, T201N and / or L235M, wherein the one or more amino acid substitutions in VP3 VR include VR-I A263E, S264T, T265A, A267S and / or S268T, and Wherein the further VP3 amino acid substitutions include H272T and / or H642N.

22. The chimeric AAV capsid of claim 21, wherein the one or more amino acid substitutions in the VP1 and / or VP2 include D41N, F129L, K168R, T201N or L235M, wherein the one or more amino acid substitutions in VP3 VR include VR-I A263E, S264T, T265A, A267S and S268T, and Further VP3 amino acid substitutions included H272T and H642N.

23. The chimeric AAV capsid of any one of claims 20-22, comprising, consisting essentially of, or consisting of an amino acid sequence that is at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO: 11 (AAVH67).

24. An AAV particle comprising: The chimeric AAV capsid according to any one of claims 1-23; and AAV vector genome; wherein the AAV capsid encapsidates the AAV vector genome.

25. The AAV particle of claim 24, wherein the AAV vector genome comprises a heterologous nucleic acid molecule.

26. The AAV particle of claim 25, wherein the heterologous nucleic acid molecule encodes CRISPR RNA, CRISPRRNP, antisense RNA, microRNA, or RNAi.

27. The AAV particle of claim 25, wherein the heterologous nucleic acid molecule encodes a polypeptide.

28. The AAV particle of claim 25, wherein the heterologous nucleic acid molecule encodes a therapeutic polypeptide.

29. A nucleic acid molecule encoding the chimeric AAV capsid of any one of claims 1-23.

30. A vector comprising the nucleic acid molecule according to claim 29.

31. The vector of claim 30, wherein the vector is a plasmid, a bacteriophage, a viral vector, a bacterial artificial chromosome or a yeast artificial chromosome.

32. The vector of claim 31, wherein the viral vector is an AAV vector, an adenoviral vector, a herpes virus vector, a lentiviral vector, an alphavirus vector or a baculovirus vector (e.g., an AAV particle, an adenoviral particle, a herpes virus particle, a lentiviral particle, an alphavirus particle, a baculovirus particle, etc.).

33. The AAV vector of claim 32, wherein the nucleic acid molecule further comprises an AAV rep coding sequence.

34. A cell (e.g., an in vitro cell) comprising the chimeric AAV capsid of any one of claims 1-23, the particle of any one of claims 24-28, the nucleic acid molecule of claim 29, or the vector of any one of claims 30-33.

35. The cell of claim 34, wherein the nucleic acid molecule is stably incorporated into the genome of the cell.

36. A method for producing a recombinant AAV particle comprising an AAV capsid, the method comprising: Providing / introducing into cells in vitro under conditions that allow assembly of the recombinant AAV particles comprising the AAV capsid and encapsidating the AAV vector genome comprising the heterologous nucleic acid molecule The nucleic acid molecule of claim 29, the AAV rep coding sequence, the AAV vector genome, and helper functions for generating a productive AAV infection.

37. An AAV particle produced by the method of claim 36.

38. A pharmaceutical formulation comprising the AAV particles of any one of claims 24-28 or 37, the nucleic acid of claim 29, the vector of any one of claims 30-33 and / or the cells of claim 34 or 35 in a pharmaceutically acceptable carrier.

39. A method for delivering a nucleic acid molecule to a neural cell (e.g., including cells of the peripheral and central nervous systems, e.g., brain cells such as neurons, oligodendrocytes, glial cells, microglia, astrocytes, e.g., spinal cord such as cervical, thoracic, lumbar, sacral neurons and / or dorsal root ganglion (DRG) neurons), the method comprising contacting the neural cell with an AAV particle according to any one of claims 24-28 or 37, a nucleic acid according to claim 29, a vector according to any one of claims 30-33, a cell according to claim 34 or 35, and / or a pharmaceutical formulation according to claim 38.

40. A method of delivering a nucleic acid molecule to a neural cell of a mammalian subject, the method comprising: Administering an effective amount of the AAV particles of any one of claims 24-28 or 37, the nucleic acid of claim 29, the vector of any one of claims 30-33, the cells of claim 34 or 35, and / or the pharmaceutical formulation of claim 38, thereby delivering the nucleic acid molecule to the neural cells of the mammalian subject.

41. A method of treating a disorder (e.g., a CNS disorder, e.g., a PNS disorder) in a mammalian subject in need thereof, wherein the disorder is treatable by expressing a nucleic acid molecule encoding a therapeutic product in the nervous system of the subject, the method comprising administering to the mammalian subject a therapeutically effective amount of an AAV particle according to any one of claims 24-28 or 37, a nucleic acid according to claim 29, a vector according to any one of claims 30-33, a cell according to claim 34 or 35, and / or a pharmaceutical formulation according to claim 38, under conditions such that the nucleic acid molecule encoding the therapeutic product is expressed in the nervous system, thereby treating the disorder.

42. The method of claim 41, wherein the disorder is Parkinson's disease, Huntington's disease, Rett syndrome, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), epilepsy, Alzheimer's disease (GDF; neprilysin), Batten disease (ceroid lipofuscinosis neuronal protein [CLN] 1-10), Friedreich's ataxia (FRDA, Friedreich's ataxia gene [FXN]), brain trauma, spinal cord injury (SCI), ischemic and hypoxic CNS diseases, brain and spinal cord tumors, or any combination thereof.

43. The method of any one of claims 40-42, wherein the mammalian subject is a human subject.

44. The method of any one of claims 40-43, wherein the AAV particles are delivered or administered to the nervous system.

45. The method of any one of claims 40-44, wherein the AAV particles are delivered or administered to the gray matter of the subject.

46. ​​The method of any one of claims 40-45, wherein the AAV particles are delivered or administered to the spinal cord (e.g., the cervical, thoracic, lumbar, and / or sacral spinal cord region).

47. The method of any one of claims 40-46, wherein the AAV particles are delivered or administered to the subject by intrathecal, intracerebral, intraparenchymal, intracerebroventricular, intranasal, intraauricular, intraocular or periocular delivery, intravenous delivery (IV), or any combination thereof.

48. The method of any one of claims 40-47, wherein the mammalian subject has previously received gene therapy treatment with AAV particles of a serotype other than the serotype corresponding to the wild-type first AAV serotype.

49. The method of any one of claims 40-48, wherein the therapeutically effective amount of the AAV particles is about 1×10 12 Viral genomes (vg) / kg is about 1×1014 vg / kg.

50. The method of claim 49, wherein the therapeutically effective amount of the AAV particles is about 1×10 12 vg / kg to about 1×10 13 vg / kg.

Citation Information

Patent Citations

  • Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer

    US20030017131A1

  • Compositions and methods for combined therapy of disease

    US20060287259A1

  • Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins

    US20070026076A1

  • Treatment for heart disease

    US20070059288A1

  • AAV8 Vector with Enhanced Functional Activity and Methods of Use Thereof

    US20140037585A1